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Chapter 1 
 
INTRODUCTION 
 
 The Clostridia species Clostridium botulinum and Clostridium tetani are 
known for their ability to produce and release two incredibly potent and deadly 
neurotoxins. These toxins, botulinum and tetanus, have a long history as 
neuroparalytic agents in man that continues into modern times. Considerable 
work has been done to define and understand the mechanisms of pathogenesis 
attributed to these toxins. These toxins are remarkable in their similarity and their 
differences in both form and function. Structural aspects of both toxins continue 
to be defined and examined. Here, I present structural analyses of tetanus 
neurotoxin and botulinum neurotoxin progenitor complexes. Results from this 
work improve our understanding of their structural organization and helps us to 
conceptualize the role of their structure during disease.  
 
Historical Overview 
Pathogenic microbes have sickened people since our earliest societies; 
our history is full of accounts of pandemics and plagues [1,2]. The origins of 
infectious diseases were ill defined and mysterious. By the 16th century there was 
limited recognition that a “contagion” was at work in some diseases, such as 
syphilis [3] or bubonic plague [4], yet the contagion itself remained unrecognized. 
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During the 17th century Robert Hooke and Antoni van Leeuwenhoek each 
manufactured their own microscopes and observed the microorganisms that 
inhabited an unseen world [5]. The correlation between microbes and disease 
was not recognized at the time. However, their introduction of the microscope 
and the discovery of microorganisms began mankind’s foray into microbiology. 
The research and findings of Louis Pasteur and Robert Koch during the 
mid to late 19th century marked the beginning of an era for the germ theory of 
disease. The work of the these two individuals not only exposed the vastness of 
the microbial world but also defined specific guidelines for the study of these 
organisms and their role in disease [6]. It was with these tools in hand that 
researchers began to define the causative agents of many microbial related 
diseases.  
The neuroparalytic diseases botulism and tetanus have sickened humans 
and animals for thousands of years. The debilitating flaccid or spastic paralysis 
associated, respectively, with these two diseases is the result of intoxication with 
either botulinum neurotoxin (BoNT) or tetanus neurotoxin (TeNT). Each clostridial 
neurotoxin (CNT) is produced by bacteria commonly found in soil. The existence 
of these bacteria and their damaging neurotoxins wasn’t discovered until the late 
19th century [7,8]. The diseases associated with the toxins continue to be of 
serious medical concern but are also appreciated for their potential in beneficial 
clinical applications. 
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Historically, tetanus is most associated with military medicine. Its earliest 
accounts coincide with observations made on wounded soldiers. Symptoms of 
tetanus are described as spastic paralysis in a soldier with a head injury in a 
3,500-year old Egyptian surgical treatise [9].  The term tetanus comes from the 
Greek word tetanos, a derivation of teinein, to stretch. In the 4th century 
Hippocrates described the symptoms of tetanus in his writings [10]. The painting 
Opisthotonos by Sir Charles Bell [11] depicts a wounded soldier from the 
Napoleonic Wars locked in a hyperextended spasm. The connection between 
wounds and the symptoms of tetanus were recognized in early medicine, but the 
details of their relationship would not be discovered until the late 19th century. 
In contrast to tetanus, accounts of botulism before the 18th century are 
rare because the association of paralytic death and food consumption was not 
yet recognized. However, it has been theorized that ancient dietary laws and 
taboos may have originally been created to discourage the intake of poisonous 
food [12]. During the Middle Ages an edict from Emperor Leo VI of Byzantium 
forbade the consumption of blood sausages after what likely was a botulism 
outbreak [13] suggesting an awareness of the link between poisoned food and 
paralysis. When an outbreak of botulism occurred in 18th century Germany 
members of its medical community investigated the cause and linked the 
sickness to consumption of blood sausages. Theories on the “sausage 
poisoning” origin ranged from food contamination with cyanide to, notably, the 
presence of a zoonotic or organic poison [12]. An early 18th century medical 
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officer named Justinus Kerner became the first person to document cases of 
foodborne botulism. His systematic account of cases and their observed 
symptoms culminated in an 1820 monograph on sausage poisoning. Kerner 
suggested the disease was caused by “fatty acid”, a biological poison, [14] that 
had developed in the sausage. In 1870 John Müller, a German physician, 
renamed the sickness related to “sausage poisoning” to “botulism” using the Latin 
word for sausage, botulus [15]. It would be another 30 years before the causative 
agent of botulism was identified as a bacterial toxin. 
In 1884 Antonio Carle and Giorgio Rattone proved that tetanus was an 
infectious disease. They reproduced the disease in rabbits by inoculation with 
pus from a wound of a tetanus victim. They hypothesized that the spastic 
paralysis of tetanus was due to a causative agent living in nerves [16]. Also in 
this year, Arthur Nicolier observed the development of tetanus in animals after 
injecting them with soil. Upon looking at the soil samples by microscope he 
observed numerous rod-shaped bacteria present. The same bacteria were also 
recovered from the injection site on the rabbits, leading him to hypothesize that 
these bacteria were the source of the disease. He proposed naming the bacteria 
Bacillus tetanus [8]. He found no evidence that the bacteria spread throughout 
the body and instead suggested that a toxic substance was released from the 
bacteria at the site of infection [17]. Shibasburo Kitasato, a researcher trained in 
Robert Koch’s laboratory, successfully isolated Bacillus tetanus from the wound 
of a patient in 1889. This was an impressive feat. Initially, his specimen 
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contained multiple species of bacteria including a population of spores. By 
heating the sample he killed the other bacteria and recovered a pure sample of 
the sporulated bacteria. He discovered that the bacteria would only grow in an 
anaerobic environment. Upon having a pure culture of Bacillus tetanus he 
satisfied Koch’s postulates and confirmed that this isolated organism was the 
source of tetanus [7]. A year later in 1890 Knud Faber, a Dutch scientist, 
demonstrated that a soluble protein released by the bacteria in its growth 
medium was the actual source responsible for all of the symptoms of tetanus 
[18]. Also in this year, Emil Behringand and Kitasato published a report for a 
potential tetanus antitoxin [19]. They demonstrated that rabbits inoculated with 
non-lethal doses of pure C. tetani culture were no longer at risk when challenged 
later with a lethal concentration of the bacteria. They also injected whole blood or 
serum from the pre-treated rabbits into mice. The mice that had received blood or 
serum from the pre-treated rabbits survived subsequent challenge with the 
bacteria, thus indicating that something in the blood could inactivate the toxin. 
This important discovery not only introduced a real possibility for the prevention 
of tetanus and other toxin mediated diseases [20] but also introduced the world to 
the nascent field of immunology. 
In 1895 Emile Pierre Marie van Ermengem, another microbiologist trained 
in Robert Koch’s laboratory, determined the true source of botulism when several 
people became fatally ill with the disease after eating raw salted ham. Ermengem 
isolated rod-shaped, anaerobic bacteria from both the ham and the organs of a 
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victim and showed that this organism produced flaccid paralysis in test animals. 
In his 1897 report he proposed naming the new bacteria Bacillus botulinus. He 
also determined that a soluble protein released by the bacteria into its liquid 
culture was sufficient to cause botulism in test animals [8].  
Based on the work of Kerner and Van Ermengem it was assumed that 
botulism only occurred in contaminated meat. This assumption changed in 1904 
after a lethal outbreak of botulism was traced back to Bacillus botulinus in canned 
beans [21]. In 1910 antitoxins that were made for the bacteria isolated from 
salted ham in 1897 and the beans in 1904 were tested against one another. This 
test revealed that the two strains were immunologically distinct and therefore 
required different neutralizing antitoxins [22]. These BoNT serotypes were later 
classified alphabetically as type A and type B [23].  
The revelation that BoNT possesses genotypic diversity has prompted 
over 100 subsequent years of research in pursuit of understanding its serological 
differences and the bacteria that produce them. 
 
Neurotoxigenic Clostridia 
 
Classification 
 To differentiate between aerobic, spore-forming organisms and 
anaerobic, spore-forming organisms the 1924 Committee on Classification of the 
Society of American Bacteriologists suggested use of the generic terms Bacillus 
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and Clostridium [24]. As a result, the neurotoxigenic, anaerobic bacilli were now 
classified as either Clostridium tetani or Clostridium botulinum.  
The genus Clostridium contains over 100 species, 35 of which are 
pathogenic [25]. The genus varies phylogenetically but is traditionally defined as: 
gram positive, spore-forming, anaerobic, rod-shaped bacteria [25]. In unfavorable 
growth conditions, these bacteria produce an intracellular endospore to contain 
their genome and essential metabolic machinery before entering a dormant 
phase [26]. The endospores possess a thick protective coat that is resistant to a 
range of high temperatures and other environmental insults. The endospores of 
C. tetani and C. botulinum are wider than the cell and located at its terminal end 
[27] giving the bacteria a ‘spindle-like’ shape from which the name Clostridium 
derives [13]. 
The neurotoxigenic clostridia C. tetani and C. botulinum are classified by 
which type of toxin is produced by the organism. This is a satisfactory approach 
for C. tetani because toxin synthesis only occurs in a uniform group of bacteria in 
this species and only one serotype of that toxin has been identified. The TeNT 
encoding gene is located on a plasmid and its presence or absence determines 
whether or not the organism is toxigenic [13,28].  
Classification of C. botulinum is more complicated due to the phylogenetic 
diversity of the organisms that can produce BoNT. For this reason C. botulinum 
is reserved for all bacteria with the ability to produce the neurotoxin [29]. From 
the early 1900s to as recently as 2013 eight different immunologically distinct 
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serotypes (designated with the letters A-H) have been identified [29,30]. Multiple 
subtypes within each serotype have been determined by differences in amino 
acid sequence [29,30]. The taxonomy of the organisms that produce BoNT 
includes members of C. botulinum, C. argentinense, C. butyricum, and C. baratii 
all of which have been classified into six groups representing their physiological 
and genetic differences [31,32] (Table 1-1). 	  
Group I contains proteolytic C. botulinum serotypes A, B, F, and H. 
Bacteria in this group can release a variety of extracellular enzymes to obtain 
nutrients [33,34]. This group also contains an array of subtype strains some of 
which possess more than one neurotoxin gene that may or may not have activity 
[35]. Depending on the subtype, the BoNT gene is located either on the 
chromosome or a plasmid. BoNT/A and /B serotypes are commonly associated 
with food borne or wound botulism in humans [36]. Bacteria in this group form 
hardy spores that are distributed widely in soil.  
Group II members are non-proteolytic bacteria and do not release 
extracellular enzymes. This group contains C. botulinum strains that produce 
BoNT serotypes and subtypes of B, E, and F [37]. Group II serotypes B and E 
are often associated with foodborne botulism from salted or smoked fish or meat 
[36]. Bacteria in this group only have a single neurotoxin gene that is located on 
either the chromosome or a plasmid [38]. Bacterial spores from this group are 
less heat resistant than Group I but remain widely distributed in soil and sediment 
[25]. 
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C. botulinum serotypes and subtypes C and D are in Group III. These 
serotypes are heavily associated with avian and animal botulism. Strains in this 
group are either weakly proteolytic or lack proteolytic activity and the neurotoxin 
gene is located on a bacteriophage [29,39]. Groups IV – VI represent other 
clostridia species capable of producing BoNT [29,40]. C. argentinense, of Group 
IV, produces BoNT/G only. This proteolytic bacteria was originally isolated from 
Argentinian soil samples [41] and is not associated with botulism in humans. 
Groups V and VI contain neurotoxigenic strains of BoNT/E producing C. 
butyricum and some strains of BoNT/F making C. baratii. Both groups have been 
implicated in cases of human botulism [42,43]. 
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Table 1-1. Characteristics of neurotoxigenic clostridia 
  C. botulinum    
Characteristic C. tetani Group I Group II Group III Group IV1 Group V2 Group VI3 
Toxin Type TeNT A, B, F, H B, E, F C, D G E F 
Gene Location4 P C, P C, P bp P C P 
Spore Heat Resistance5 84 104-121 77-82 104 82-120 30-37 30-37 
Proteolysis - + - - + - - 
 
1
 C. argentinense 
2
 C. butyricum 
3
 C. baratii 
4
 P = plasmid, C = chromosome, bp =bacteriophage [31,44,45] 
5
 Heat resistance temperatures in °C 
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Toxin Genetics  
 TeNT is not associated with foodborne illness and BoNT is. Both 
neurotoxins are 150 kDa proteins that are susceptible to protease activity in the 
digestive tract. However, many C. botulinum strains produce BoNT and 
neurotoxin-associated proteins (NAPs). At low pH the toxin and NAPs non-
covalently interact to form progenitor complexes (PCs) [30]. The NAPs include 
three hemagglutinin-like (HA) proteins (HA1, HA2, and HA3) and a non-toxin, 
non-hemagglutinn protein (NTNH). Other BoNT strains don’t have the HA genes 
and produce smaller PCs. BoNT is orally toxic because the PC assembly 
protects the neurotoxin from degradation as it passes through the digestive tract 
[46,47]. TeNT has no NAP genes and forms no PCs making it susceptible to 
proteolysis [28]. These differences between the neurotoxins are reflected in their 
respective genetic organization. Figure 1-1 depicts the gene loci for TeNT and for 
the BoNT serotypes most commonly associated with foodborne botulism. 
The TeNT gene locus consists of a single operon that contains genes for a 
neurotoxin expression regulator, tetR, and the neurotoxin. No genes for NAPs 
are present [48]. By comparison, the BoNT gene locus is comprised of two 
operons separated by botR, a tetR homologue that regulates BoNT and NAP 
expression [31,38,49,50]. Some serotypes and subtypes may vary in their 5’ 
genetic organization, but the 3’ part of the locus is conserved [38]. The HA genes 
are clustered together in one operon while the NTNH and BoNT are clustered in 
the other. The organization for type is E differs from A and B in that it does not 
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express HA genes or encode for the expression regulator botR. Rather than an 
HA operon, the type E equivalent contains orfX genes. The function of the OrfX 
proteins is currently unknown. The NTNH and BoNT/E genes are in a separate 
operon adjacent to a p47 gene. The function of p47 has not been determined 
either [51].  
 
 
 
Figure 1-1. The genetic organization of TeNT and BoNT serotypes A, B, and 
E. TeNT in C. tetani is located in a single operon that contains an alternative 
sigma factor, tetR. The BoNT gene locus for toxins type A, B, and E in C. 
botulinum has two operons. One operon contains the HA genes and the other 
has the genes for NTNH and BoNT. The operons are separated by the 
alternative sigma factor, botR. C. botulinum type E does not express HA proteins 
and instead has an orfX operon adjacent to its NTNH and BoNT genes. 
 
Virulence Factors and Toxicity  
In addition to TeNT, C. tetani produces a second toxin named tetanolysin. 
The gene for this second toxin is encoded for on the chromosome and is not 
considered part of the TeNT gene locus [28]. This cholesterol-dependent 
cytolysin can form pores and lyse red blood cells but its exact role in 
pathogenesis continues to be defined. It is thought that this lytic activity may also 
help TeNT disseminate through tissues [52,53]. The proteolytic C. botulinum 
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genome contains a nine-gene cluster that is highly similar to streptolysin from 
Streptococus [34] however there is no direct evidence that this results in a 
cytolytic toxin of its own. C. botulinum does, however, produce a binary toxin 
referred to as C2 [54]. The toxin does not cause paralysis and is not considered a 
neurotoxin. The ADP-ribosylation activity of C2 toxin interferes with actin 
assembly in the cell and alters cell function [55]. 
Recent genomic sequencing of C. tetani and representative Group I 
(proteolytic) C. botulinum strains has revealed that in addition to their neurotoxins 
and respective secondary toxins, there are several genes present whose 
products are predicted to influence the virulence of the organisms These include 
collagenases, fibronectin-binding proteins, surface layer proteins with adhesive 
properties, and chitinases [34,48]. Additional virulence factors for non-proteolytic 
C. botulinum are currently not well understood [37].  
BoNT and TeNT are the principal virulence factors for their respective 
neurotoxigenic clostridia and are generally considered the first and second most 
potent toxic substances of biological origin [27]. The toxins share several 
characteristics, such as similar molecular weights, molecular structures, and 
modes of action. The potency of TeNT and BoNT has been evaluated in a 
number of animal models (reviewed in [56]) however toxicity estimates can be 
difficult to compare due to variations in assay and toxin purification [57,58]. 
Extrapolation from animal studies and accidental intoxication in humans suggests 
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that the calculated intravenous lethal doses for BoNT/A or TeNT are 
approximately 1 ng/kg and <2.5 ng/kg respectively [56,57].  
Toxin produced by C. botulinum in culture or in foodstuffs exists as a 
heterogeneous population of free BoNTs, NAPs, and various sized PCs. Studies 
have shown that ingestion of free BoNT can be orally toxic if the dose is very high 
[59–61]. Interestingly, ingestion of BoNT in its complexed (PC) form dramatically 
increases its oral toxicity. The oral mean lethal dose (MLD50) of the BoNT-PC in 
mice decreases as the PC size increases, suggesting that the larger PC 
assemblies promote BoNT passage through the gastrointestinal tract [62,63] 
(Table 1-2).  
The BoNT and NAPs interact to form high molecular weight PCs. 
Ultracentrifugation studies on the complex have shown that the PCs regularly 
adopt three different sizes. These differences in size are indicated by their 
individual sedimentation rates. Uncomplexed BoNT has a molecular weight of 
150 kDa and sedimentation rate of 7S. The other sizes formed include: 12S (M-
PC, ~300 kDa), 16S (L-PC, ~500 kDa), and 19S (LL-PC, ~900 kDa). The 19S PC 
has only been observed with BoNT/A and is predicted to be a dimer of 16S PCs 
(reviewed in [30]). The PC sizes are dependent on the toxin serotype and the 
number of NAPs assembled in the complex.  
Biochemical studies have determined that the NTNH protein association 
with BoNT is sufficient to protect the toxin form digestive conditions such as low 
pH in the stomach or the presence of digestive enzymes [47,64]. A recent 
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structure of a 12S complex shows the BoNT and NTNH as an interlocked 
complex that prevents degradation in acidic or proteolytic conditions [47]. The 
role of the HA proteins in the complex are less clear and theories continue to 
evolve. These will be discussed in more detail in the upcoming section on 
Research Objectives.  
 
Table 1-2. BoNT PC size, NAP composition, and oral toxicities for 
serotypes commonly associated with disease in humans 
 
Type Molecular Size Components Oral LD501 
A 19S, LL, 900 kDa BoNT, NTNH, HA1, HA2, HA3 (a 16S dimer?) 
120 
 16S, L, 500 kDa BoNT, NTNH, HA1, HA2, HA3 2,200 
 12S, M, 300 kDa BoNT, NTNH 3,600 
 7S, S, 150 kDa BoNT 43,000 
    
B  16S, L, 500 kDa BoNT, NTNH, HA1, HA2, HA3 1.5 
 12S, M, 300 kDa BoNT, NTNH 1,100 
 7S, S, 150 kDa BoNT 24,000 
    
E 12S, M, 300 kDa BoNT, NTNH 220 
 7S, S, 150 kDa BoNT >750 
1Oral LD50 as equivalent number of i.p. LD50 x 10-3; in mice [62,63] 
 
Tetanus and Botulism 
Tetanus and Botulism are forms of infectious disease yet neither disease 
is contagious. The neurological dysfunction associated with each disease results 
from intoxication with either TeNT or BoNT. Both diseases manifest as forms of 
debilitating paralysis that are potentially life-threatening. 
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Symptoms 
Generalized tetanus may occur in adults, infants, and animals after C. 
tetani spores are introduced to anaerobic conditions in a wound. This is the most 
common form of tetanus and represents the majority of documented cases. 
Neonatal tetanus is included in this category as it involves C. tetani infection in 
the umbilical cord stump [65].  The bacterial spores germinate in low oxygen 
conditions releasing TeNT into the body. The toxin binds to nerve terminals 
throughout the body to gain eventual entry into its target: motor neurons in the 
central nervous system (CNS). Symptoms occur when the neurotoxin prevents 
the release of inhibitory neurotransmitters at synaptic junctions used to quench 
nerve impulses. Symptoms of tetanus first appear in the head and neck region 
because of their shorter axonal pathways. The toxin prevents relaxation of 
inhibitory antagonist muscle groups and results in agonist and antagonist muscle 
groups contracting simultaneously [66]. Tetanus is commonly referred to as 
“lockjaw” because one of its first symptoms involves the tightening of jaw 
muscles until the infected individual can no longer open their mouth. Ironically, 
contractions in other facial muscles cause the appearance of a pained smile (25). 
An infected individual will experience painful, uncontrollable muscle contractions 
and spasms that descend into the chest and limbs. The spastic paralysis 
resembles convulsions and can be powerful enough to rupture tendons and 
fracture bones. The paralysis can also prevent normal respiration and can result 
in death if untreated [65]. Less common forms of the disease either only affect a 
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localized area around the wound (local tetanus) or only cranial nerves in the face 
after a head injury (cephalic tetanus) [67]. 
Botulism may also occur in adults, infants, and animals. Like tetanus, 
botulism can result from an infected wound but it also has four other recognized 
forms. Symptoms of botulism are the same regardless of its form and begin after 
exposure to BoNT. The neurotoxin disrupts signals at junctions between nerves 
and muscles in the peripheral nervous system and prevents muscle contraction 
[29]. Symptoms begin with fatigue, weakness and vertigo, usually followed by 
blurred vision, difficulty swallowing and talking. Facial muscle control is lost from 
palsy of the cranial nerves. The disease descends as a symmetric flaccid 
paralysis into the core and limbs. Nausea, constipation and abdominal swelling 
may also occur. In severe cases paralysis inhibits the contraction of respiratory 
and cardiac muscles and can result in death without treatment [68,69].  
 
Botulism Forms 
Wound  
     Much like tetanus, wound botulism occurs when a wound is contaminated 
with C. botulinum spores from the environment. The spores germinate in the 
anaerobic conditions of an abscess and BoNT is released into the body. This 
form of botulism was considered rare until recently. The condition has become 
more common since the early 1990s. The number of cases of wound botulinum 
has increased significantly worldwide and nearly all of these cases involve 
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heroin-injecting drug users [68]. The form of heroin being injected (either 
intravenously or subcutaneously) is a dark colored morphine derivative that is 
considered less refined than white heroin. Called black tar heroin, it is ‘cut’ or 
diluted with a variety of substances including soil. As a result C. botulinum spores 
can inadvertently contaminate the drug and be exposed to wounded areas on a 
drug-user [70]. 
 
Foodborne 
 The foodborne version of botulism is considered the classical form of the 
disease because of its history with food [69]. While tetanus is only associated 
with compromised wounds, botulism can also occur as a result of ingesting 
preformed-BoNT PCs in contaminated food. C. botulinum spores can survive 
many food preservation methods designed to kill nonsporulating organisms [71]. 
The spores can vary in their resistance to heat and many strains require 
temperatures above boiling to ensure their destruction. Surviving spores 
germinate and release toxin complexes in foods with an anaerobic environment, 
a pH over 4.5, and low sugar or salt content [72]. Foodborne botulism primarily 
occurs because the naturally occurring complexed form of BoNT is protected as it 
passes through the gastrointestinal tract [46,47]. Once in the small intestine the 
toxin makes its way into the bloodstream and then selectively targets and binds 
to neurons in the periphery [73]. BoNT serotypes /A, /B, and /E have each been 
associated with foodborne botulism.  
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Intestinal (Adult and Infant) 
 In contrast to foodborne botulism, intestinal botulism results from 
absorption of BoNT produced in situ by ingested C. botulinum spores that have 
germinated and colonized the gastrointestinal tract. Adult cases are rare and 
generally involve individuals who have had surgical procedures on their bowels 
and are on antibiotics [74,75]. Antibiotics in adults can reduce the population of 
normal flora in the intestine providing C. botulinum an anaerobic environment 
with limited competition from other species of bacteria.  
Infant botulism is the most common form of the disease and also occurs 
when C. botulinum colonize the intestine and produce BoNT in situ [68]. Infants 
under the age of one are susceptible because their intestinal flora are not 
established enough to compete with C. botulinum. This disease is most 
associated with infants consuming honey (which can contain C. botulinum 
spores) but cases have also been linked to improperly home-canned baby food 
and contaminated milk products [76]. Botulism symptoms in infants resemble the 
adult form of flaccid paralysis but also include constipation, weak cry, inability to 
feed, loss of head control, and decrease in spontaneous movements [36,37]. 
 
Inhalation 
 This form of botulism is not a naturally occurring disease but its extreme 
potency and the increasing risk of bioterrorism requires that its threat potential be 
considered. The disease could potentially be acquired from the absorption of 
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deliberately released aerosol of the toxin. Studies have shown that inhaled 
BoNT/A can bind and transcytose across airway epithelial cells and eventually 
cause disease [77]. 
 
Iatrogenic 
 This is a recent form of botulism that can be caused by injection of BoNT 
for cosmetic or therapeutic purposes. Recommended doses for cosmetic uses 
are too low to cause disease symptoms however there have been observed 
botulism-like symptoms after intramuscular injections of the toxin [78]. Four 
people became extremely sick after receiving injections of unlicensed, highly 
concentrated BoNT for cosmetic purposes in 2004 [79]. 
 
Epidemiology 
 C. tetani and C. botulinum spores can endure many adverse conditions 
and as a result these bacteria are widely distributed in nature. Intoxication with 
either toxin is generally regarded as a “rural” concern but the toxigenic spores are 
ubiquitous and can cause disease in urban and non-urban communities [80–83]. 
Spores of toxin producing strains can germinate in practically any anaerobic 
environment with adequate energy sources [29].  
Tetanus transmission occurs when wounds become contaminated with C. 
tetani spores. Tetanus is a vaccine preventable disease and cases are relatively 
rare in many developed nations due to wide spread vaccination efforts. However, 
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cases persist in the un-vaccinated or with intravenous drug users [67]. The 
disease remains prevalent (especially neonatal tetanus) in the developing world 
where disease treatment is usually inaccessible or unaffordable [84]. 
Cases of infant or wound botulism have continued to increase in frequency 
worldwide while cases of foodborne botulism remain comparatively rare [85]. 
Most foodborne outbreaks are limited in their size and the disease is normally 
traced back to the consumption of improperly prepared home-canned foods. 
Pickled, salted, or smoked fish dishes have also been implicated in outbreaks 
[68]. Industrial food processing techniques employ a number of preventative 
measures to reduce the potential for C. botulinum spores in food products; the 
disease severity and the threat of widespread exposure to poisoned food require 
them. However, commercial food products are still vulnerable, and companies 
understand the public relations and financial risks foodborne outbreaks can 
provoke [86–89]. 
 
Treatment 
 In 1890, Behring and Kitasato [19] discovered the presence of tetanus 
antitoxin in the serum of animals who survived lethal challenges with the toxin.  
The tetanus antitoxin was specific to TeNT and could not protect against a 
challenge with another type of toxin. The potential for passive immunization 
treatments in humans became immediately apparent. Sheep and horses were 
used to scale up production of antitoxins against diphtheria [90] or TeNT. To 
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prevent allergic reactions against the antitoxin containing animal serum, a 
tetanus vaccine was pursued. A 1924 publication from the Pasteur Institute 
detailed the procedure for making an effective tetanus toxoid vaccine using toxin 
exposed to formaldehyde and heat [91]. By 1926 the tetanus toxoid was used as 
a vaccine in humans [92] and it is essentially the same formulation used today. 
Further advances for tetanus vaccination involve the addition of adjuvants to 
stimulate a stronger immune response [93].  
 Work on the tetanus vaccine laid the groundwork for the development of 
the first botulinum vaccine in 1924 [94] and the first reported use of botulinum 
toxoid on humans came in 1934 [95]. A bivalent type AB toxoid was developed 
for use by soldiers during World War II [96]. Currently, there are two primary 
antitoxins available for the treatment of botulism. These antitoxins are collected 
from horse serum and are formulated to neutralize multiple serotypes, however, 
these toxoids are not widely available and are generally reserved for military 
personnel and laboratory researchers at risk of exposure [97].  Infant botulism is 
treated with an antitoxin derived from human serum rather than horse to prevent 
possible allergic reactions [98,99]. 
 Both TeNT and BoNT can be prevented by vaccination. The only specific 
treatment for tetanus or botulism entails the administration of the appropriate 
antitoxin. The antitoxin can only neutralize toxin molecules that have not yet 
bound to nerve endings. Toxin neutralization reduces disease severity but 
paralytic symptoms cannot be stopped once the toxins have entered their target 
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neurons. Additional treatment strategies may include treatment with antibiotics to 
eradicate toxin-producing clostridia in wounds. Patients with tetanus may be 
sedated to reduce the severity of spasms [66] and severe cases of either disease 
require mechanical ventilation and supportive intensive care treatment to prevent 
death from acute respiratory failure. Cases of tetanus may necessitate intensive 
care unit admission for 3-5 weeks [66] while cases of botulism may require 
weeks to months of hospital care [68]. 
 
Neurotoxins as Bioweapons and Medicine 
   Humans have used bioweapons throughout history. Disease-causing 
agents such as viruses, bacteria, or toxins have been utilized for assassinations 
or against entire populations [100]. Bioweapons wield great power in their 
potential to cause massive casualties to an enemy, however their actual efficacy 
largely depends on factors such as potency, stability, delivery and dispersal 
[101]. Regardless, bioweapons also possess a psychological power. They have 
the power to reduce a population to panic and overreaction [102]. 
 There have been numerous attempts to use BoNT as a bioweapon. The 
relative ease of its cultivation and its extreme potency make it an attractive 
candidate for use. The threat of a bioterrorist attack with BoNT is considered a 
credible risk and many measures have been imposed to regulate the toxin and to 
prepare health workers in the wake of a large outbreak [103–106]. At the Centers 
for Disease Control, potential biological terrorism agents with the ability to inflict 
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mass casualties, public fear, and civil disruption are classified as category A 
select agents. Members of this group include anthrax, small pox, plague, and 
botulinum neurotoxin. 
 Paradoxically, in recent years BoNT has been recognized for its 
therapeutic potential in the treatment of a number of disorders characterized by 
involuntary movements from hyperactive muscles [107]. BoNT is able to disrupt 
neurotransmission required for muscle contraction, often for prolonged periods, 
and clinicians now use small, localized doses of the toxin to alleviate the 
symptoms of several muscle disorders including: head, neck, and limb dystonias, 
hemifacial spasms, blepharospasm, and hyperhidrosis (reviewed in [108]). 
TeNTs disruption of neurotransmitters required for muscle relaxation has not yet 
been used as a therapeutic [28]. However, there is growing interest in exploring 
TeNTs biological properties as a means of addressing other neuromuscular 
disorders. 
 
Role of the Neurotoxins in Disease 
 
Molecular Targets of TeNT and BoNT   
  Once in the bloodstream, TeNT and uncomplexed BoNT target receptors 
located on the plasma membrane of peripheral nerve endings [65]. Gangliosides 
are found in abundance on the surface of neuronal cells [109,110] and studies in 
vitro and in vivo have shown that they act as receptors for the CNTs [111–116].  
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BoNTs also use proteins from the lumen of synaptic vesicles (SV) as co-
receptors [117–121] which has led to a dual-receptor hypothesis. It has been 
suggested that gangliosides either direct CNTs to areas of the neuronal 
membrane that are enriched in protein receptors or keep the toxins in a 
conformation favorable to receptor binding [122,123]. It is unclear if TeNT 
requires a protein co-receptor or instead relies on interaction with two distinct 
gangliosides [124,125]. Regardless, CNT binding to receptors on the surface of 
motor neurons triggers a clathrin dependent internalization event [126–128].  
The differences between the clinical symptoms of tetanus and botulism 
are the result of differences in toxin transport once in the cell (Fig. 1-2). The long 
held model for CNT neuronal uptake and trafficking holds that BoNTs exploit SV 
endocytosis and recycling for entry into motor neurons. As a result BoNT remains 
localized at neuromuscular junctions in the peripheral nervous system (PNS). 
SVs lower their pH in order to reload with neurotransmitters and this acidification 
leads to the BoNT translocation domain inserting into the SV membrane and the 
release of its catalytic domain, the LC, into the neuronal cell cytosol [129,130]. By 
contrast, after TeNT entry into the motor neuron the toxin is sorted into the fast 
axonal retrograde transport endosome that goes to the motor neuron soma in the 
spinal cord [131,132]. These endosomes do not acidify [129,133] which prevents 
translocation domain membrane insertion and LC release into the cytoplasm thus 
allowing TeNT to remain intact for the remainder of its transport [116]. TeNT 
crosses the intersynaptic space between the motor neurons and the inhibitory 
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neurons of the spinal cord where it is internalized by a SV. This vesicle does 
acidify and will release the TeNT LC into the cytosol.  
The BoNT and TeNT LCs are metalloproteases that selectively target and 
cleave specific SNARE proteins (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors) that mediate the assembly of the SV docking-
fusion complex. Proteins that are part of this assembly include: synaptobrevin, 
syntaxin, and SNAP-25 (synaptosomal-associated protein 25) [134]. TeNT, 
BoNT/B, /D, and /F cleave at different scissile bonds on synaptobreven, BoNT/A 
and /E cleave SNAP-25 and BoNT/C can cleave either SNAP-25 or synatxin. 
Cleavage on any one of these proteins disrupts the complex assembly and SVs 
can no longer release their neurotransmitter cargo. BoNT disruption of the 
SNARE complex prevents the release of acetylcholine neurotransmitters at the 
neuromuscular junction that results in flaccid muscle paralysis and dysfunction in 
the autonomous nervous system associated with botulism [135,136]. TeNT 
disruption of the SNARE complex inhibits the release of inhibitory 
neurotransmitters required for muscle relaxation and results in the spastic 
paralysis attributed to tetanus [129,137,138]. 
Over the past 50 years there have been intermittent reports of BoNT 
affecting the CNS [139,140] though how it did this remained unclear. Several 
recent experiments have explored this possibility further and have sought to 
better understand the mechanisms that effect the intracellular sorting and fate of 
CNTs in the PNS and CNS. For example, it was recently demonstrated that  
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Figure 1-2. A schematic view of a motor neuron interacting with a spinal 
cord inhibitory interneuron. The sites of action for BoNTs (purple dots) at the 
neuromuscular junction where synaptic vesicles can no longer release their 
neurotransmitter cargo (small, blue dots) and TeNTs (green dots) undergoing 
axonal retrograde transport. TeNT crosses into the inhibitory interneuron and 
prevents neurotransmitter release (small, red dots). 
 
BoNT serotypes /A and /E are capable of retrograde transport in primary spinal 
cord neurons [141,142]. Many mechanistic questions remain regarding how the 
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CNTs are sorted and transported in neurons, but it is already clear that the 
paradigm model of CNT trafficking in neurons is incomplete. 
 
TeNT and BoNT Structure and Function 
Both TeNT and BoNT are produced as inactive ~150 kDa single-chain 
proteins. The chains are post-translationally nicked into active dichain molecules 
[143] that consist of a 50 kDa light chain (LC) and a 100 kDa heavy chain (HC) 
linked by an interchain disulfide bond. CNTs have an AB toxin organization and 
consist of three ~50 kDa functional domains: binding (RBD), translocation (TD), 
and catalytic (LC) (Fig. 1-3a). The binding domain spans the C-terminus of the 
HC while the translocation domain makes up the N-terminal half of the HC.  The 
catalytic domain, found at the N-terminus of the protein, is the LC and functions 
as a zinc-endopeptidase specific for core components of the neurotransmitter 
release apparatus [144,145]. The structures for BoNT/A, /B, and /E holotoxins 
have been determined [146–148]. Types /A and /B share a similar structural 
organization while type /E has a unique organization (Fig. 1-3b). The structure of 
the TeNT holotoxin is unknown but two of its three domains have high-resolution 
structures available and have similar structures to their BoNT homologues (Fig. 
1-3c and 1-3d) [145,149]. The three CNT domains each have their own function 
but recent work by Fischer et al. [150] suggests that they also work in concert so 
that each domain chaperones the other through the intoxication process. 
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Figure 1-3. The structural organization of the CNTs. (a) The activated CNT 
has three domains linked by a disulfide bridge: the catalytic domain (LC in blue), 
the translocation domain (TD in green), and the receptor-binding domain (RBD in 
beige).  (b) The structures of BoNT/A (left) and BoNT/E (right) have different 
organizations [146,148]. (c) The TeNT RBD [149] and (d) LC [145]. The TeNT 
holotoxin structural organization is unknown.  
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Receptor Binding 
C. tetani in wounds can produce and release TeNT and other virulence 
factors such as tetanolysin. The lytic activity of tetanolysin may assist TeNT in 
gaining entry into the bloodstream where it can then target the plasma membrane 
of peripheral nerve terminals. The TeNT receptor binding domain (RBD) structure 
has been determined [112,149,151,152] and is structurally similar to the BoNT/A 
RBD. The RBD is comprised of two subdomains, an N-terminal beta-barrel and a 
C-terminal beta-trefoil fold [153]. For TeNT, these subdomains can 
simultaneously bind two polysialogangliosides found on the surface of the 
neuronal cell [28,125] to induce endocytosis.  
When considering receptor binding for BoNT one must take into account 
how the toxin reaches the bloodstream. If the toxin is released as a result of 
wound botulism its process is much like that of TeNT. BoNTs use two 
independent receptors to gain access into the neuronal cell. BoNTs first interact 
with gangliosides on the cell surface and then interact with specific protein 
receptors. The three serotypes that cause human botulism, types /A, /B, and /E, 
have been found to bind to the same subset of gangliosides (reviewed in [114]) 
and their protein receptors are also known. The protein receptors for BoNT/A and 
/E have been identified as synaptic vesicle protein 2 (SV2) while BoNT/B binds to 
synaptotagmin I or II (Syt I or Syt II) proteins [117,119,154,155]. The overall 
structure of TeNTs RBD is very similar to the BoNT RBD. The two toxins share 
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significant sequence homology in the N-terminal binding subdomain as compared 
to their C-terminal subdomains [156].  
 
Translocation 
The translocation of the CNT LC into the neuronal cell cytosol is essential 
for pathogenesis to occur. Study of the actions of this domain has refined our 
understanding on the elegant design of the neurotoxin and how all three of its 
domains guide one another during the translocation process [150,157–159]. 
There has been extensive work done to understand the structure and function of 
these toxins. Currently, there is more literature available for BoNT than TeNT on 
the translocation event, but due to their structural and functional homology it is 
likely that the process is similar between the toxins. 
 After the CNT has entered a neuron it must be able to translocate its 
catalytic domain into the cytosol. The synaptic vesicles that BoNT and TeNT use 
to gain entry into neurons (at the neuromuscular junction or at inhibitory 
interneurons in the spinal cord) produce a pH gradient in the lumen using a 
vesicular ATPase proton pump [160]. The acidification of these SVs induces a 
conformational change in the toxin structure allowing its translocation domain to 
form a pore in the vesicle membrane so that the LC is released into the neuronal 
cell cytosol. Recent experiments have shown that this conformational change 
and membrane insertion are dependent on RBD interaction with polygangliosides 
in the SV lumen [160,161] and that specific residues in all three domains of the 
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toxin are responsible for pH sensitivity [162]. It has been demonstrated that the 
TD protects the LC while in the acidic lumen environment and will eventually 
guide its exit from the SV [163]. CNTs with broken interchain disulfide bonds 
cannot form channels [164] and the LC will not be translocated. The LC is partly 
unfolded to exit the SV. Once out of the lumen the disulfide bond is reduced and 
the LC is free in the cytosol [157].  
 
Catalytic 
 The LC is probably the most studied domain in CNTs and has prompted 
numerous structural and biochemical investigations. Crystal structures are 
available for BoNT serotypes /A - /G as well as for TeNT (reviewed in [165]). All 
CNT LCs share a similar globular fold, and they all share a characteristic zinc-
binding motif (HExxH+H) for their active sites. The zinc is bound inside a large 
cavity with a high negative electrostatic potential. The LCs all use the same 
catalytic mechanism but interestingly the BoNT serotypes target different 
substrates of the neurocytosis apparatus with high specificity. This specificity is 
attributed to interactions with the substrate that are independent of the active site 
[166]. Each LC will target and cleave a specific scissile bond related to specific 
SNARE proteins that mediate SV docking and fusion [166,167]. TeNT and 
BoNT/B, /D, and /F recognize and cleave different scissile bonds located on a 
vesicle-associated membrane protein (referred to as VAMP or synaptobrevin). 
BoNT/A and /E specifically recognize and cut different peptide bonds on SNAP-
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25 while BoNT/C will cleave both syntaxin and SNAP-25 (reviewed in [168]). In 
addition to their holotoxin structures, some LCs have been co-crystallized with 
their targeted SNARE substrate [121,155,169] allowing for additional insight in 
understanding the specificity of each toxin. 
 
Research Objectives 
  
In the case of foodborne botulism the toxin must cross through epithelial 
cells in the intestine to gain access to the bloodstream. It is important to 
remember that in addition to BoNT, C. botulinum also releases NAPs that non-
covalently associate with the toxin to form a heterogeneous population of toxin 
complexes. The complexes are pH-sensitive, and disassemble at pH ≥ 7 [170–
172]. BoNT and NAPs produced at the site of an infected wound likely will not 
assemble into a PC because the pH of the circulation system is slightly basic 
[173]. Ingestion of BoNT PCs from contaminated food is orally toxic because the 
toxin is protected from the low pH of the stomach and the presence of digestive 
enzymes. Once the stomach content empties into the duodenum pancreatic bile 
salts are released to neutralize the low pH of the chyme from the stomach [174].  
The duodenum pH is maintained between 6 and 7 [175]. The question of whether 
the NAPs remain associated with BoNT long enough to play a role in intestinal 
absorption has become a controversial topic. There are reports that suggest 
BoNT will be fully released from the NAPs in the small intestine, and evidence 
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that the BoNT is capable of crossing the epithelial barrier without them 
[77,176,177].  The identity of the BoNT receptor on the epithelial surface in the 
intestine is unknown, but there is evidence to suggest that it differs from the 
protein receptors used on neuronal cells [178]. There are also reports suggesting 
that the NAPs contribute to absorption in the intestine [179]. These include 
experiments in pH 7 rat intestinal juices where the PC does not disassociate 
[180], or demonstrations that PCs are absorbed by the intestine during various 
rat ligation duodenum loop assays [181,182].  
 There is growing evidence that suggests the HA proteins may contribute to 
intestinal absorption by enhancing adhesion of the BoNT PC to mucins or the cell 
surface, disrupting the epithelial barrier, or facilitating transcytosis.  The crystal 
structures of the HA1 proteins from serotypes /A, /B, /C, and /D have recently 
been determined. Every structure except for the /D serotype was co-crystallized 
with a form of carbohydrate moiety including galactose, lactose, N-Acetyl-D-
lactosamine, N-acetylneuraminic acid, or N-acetylgalactosamine [183–185]. The 
co-crystal structures of the HA3 proteins from serotypes /A and /C with α2-3, α2-
6-sialylated oligosaccharides were also recently determined [183,186]. These 
HA1 and HA3 binding sites could represent points of contact between the BoNT 
PC and mucins, glycolipids, or glycoproteins in the intestine. Needless to say, the 
functional role of the HA proteins in the BoNT PC will require more study.  
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When I initiated this study there was very little known about the actual 
organization of the BoNT PC. There were crystal structures of assorted NAPs 
and an array of structural predictions based on biochemical assays. The oral 
toxicity associated with the BoNT PC suggests an effective protein assembly 
capable of protecting a protein during passage through the harsh conditions 
encountered in the gastrointestinal tract and then directing it to specific cell types. 
Understanding how these proteins assemble to achieve these results has the 
potential to improve the design and function of many mucosal vaccines or the 
intestinal absorption of oral biologics. A second structural unknown in the CNT 
field has been the lack of the TeNT holotoxin structure. It is unclear if its three 
domains resemble the organization of its BoNT homologues and if so whether it 
is similar to BoNT/A or BoNT/E or if its structure is unique. A better 
understanding of the complete structure of TeNT may help explain its trafficking 
differences from BoNT and may provide new approaches in drug design for 
neurological disorders. 
 I have sought to address these gaps in our structural knowledge for the 
BoNT PC and TeNT using negative stain electron microscopy (EM) and single 
particle averaging. In Chapter II of this thesis, I describe work done to image the 
PC assembly for the three BoNT serotypes responsible for human botulism. I 
was able to describe their molecular assembly using 3D reconstructions of each 
PC using the random conical tilt method as well as docking the NAP crystal 
structures into the models. In Chapter III of this work, I describe work done to 
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explore the structure of the TeNT holotoxin using negative stain EM and single 
particle averaging. I have been able to show that activation of TeNT does not 
result in a dramatic conformation change and that its overall structure does not 
resemble that of BoNT/A. 
   
 
  
	  	   37	  
CHAPTER II 
 
MOLECULAR ASSEMBY OF BOTULINUM NEUROTOXIN PROGENITOR 
COMPLEXES 
 
Introduction 
 Botulinum neurotoxin (BoNT) is produced by various strains of Clostridium 
botulinum, C. butyricum, and C. baratii and is the most potent toxin known.  
BoNT’s are classified into 7 serotypes (A–G) based upon serotype-specific 
antibody neutralization, and DNA sequencing has revealed multiple subtypes 
within each serotype [29]. The BoNT’s are synthesized as single-chain proteins 
that are proteolytically cleaved into di-chain proteins, consisting of a 50 kDa light 
chain (LC) and a 100 kDa heavy chain (HC) [122]. The HC binds receptors on 
the pre-synaptic neuron in the neuromuscular junction and directs the LC into the 
neuronal cell cytosol.  The LC is a zinc metalloprotease that cleaves components 
of the synaptic membrane fusion complex and blocks neurotransmitter exocytosis 
[144]. This inhibition of acetylcholine release in neuromuscular junctions results 
in the flaccid paralysis associated with botulism.  
In adults, the most common form of botulism results from ingestion of BoNT 
contaminated food, while in infants, the disease typically results from C. 
botulinum colonization and in situ BoNT production in the gut [187].  In the case 
of food contamination, BoNT has to survive passage through the low pH 
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environment of the stomach. In both cases, BoNT must resist protease 
degradation in the intestine, cross the epithelial barrier of the digestive tract, and 
gain access to the nerve ending targets through the blood and lymph circulatory 
systems [188].  
To maintain the activity of BoNT under these conditions, organisms that 
produce BoNT also produce one or more neurotoxin associated proteins (NAPs) 
that non-covalently associate with the neurotoxin to form progenitor complexes 
(PCs) [30].  The PCs have been shown by ultracentrifugation to adopt three 
sizes: 12S (M-PC, ~ 300 kDa), 16S (L-PC, ~500 kDa), and 19S (LL-PC, ~900 
kDa) (reviewed in [30]). The genes for the neurotoxin and its NAPs are located in 
the same locus (Fig. 2-2a) [38].  The NAPs include three hemagglutinin (HA) 
proteins (HA1, HA2, and HA3, named for their capacity to agglutinate red blood 
cells) and a non-toxic, non-hemagglutinin protein (NTNH). Type A2, E, and F 
strains do not have the HA genes and only produce the 12S PC, a noncovalent 
complex of BoNT and NTNH. Type B, C, and D strains produce the 12S and 16S 
PCs.  The 16S PC includes BoNT, NTNH, HA1, HA2, and HA3.  Type A1 strains 
produce 12S, 16S, and 19S PCs.  The 19S PC may represent a dimer of 16S 
complexes.  
The oral median lethal dose (MLD50) of BoNT decreases as the size of the 
PC increases, suggesting that the NAPs play a role in promoting BoNT passage 
through the gastrointestinal tract [62,63,189]. A recent structure of a 12S complex 
shows how BoNT/A1 and NTNH/A1 bind each other in an interlocked complex 
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that protects the BoNT from acidic and proteolytic degradation (Fig. 2-2a) [47]. 
But, the role of the NAPs in promoting transport through epithelial cells is more 
controversial.  While the NAPs do not appear to effect the transport efficiency of 
iodinated BoNT in transcytosis experiments [77,176], experiments in a guinea pig 
model suggest that only the 16S form of the BoNT/C PC is absorbed from the 
intestine and released into the serum [190].  Mechanisms for how the HA 
proteins could enhance intestinal absorption involve their capacity to bind mucins 
[118,191], bind intestinal microvilli [192], and disrupt the paracellular barrier [193].  
Crystal structures of HA1 and an HA3 trimer in complex with carbohydrates 
reveal sites where these molecules could bind mucins and sialylated 
gangliosides and/or glycoproteins of the epithelial cell surface [185,186].   
Despite these observations, there is limited information regarding the 
architecture of the BoNT 16S and 19S PCs. A two-dimensional (2D) electron 
crystallography study of the BoNT/A1 19S PC suggested features with trigonal 
symmetry [194], and individual electron microscopy (EM) micrographs of the 
BoNT/D 16S PC suggested that the complex has three extended ‘arms’ [195]. 
Here, we have generated 3D reconstructions of the BoNT/A1, /B, and /E PCs, 
building on a series of 2D class averages obtained by single particle EM and the 
random conical tilt (RCT) approach [196]. 
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Methods 
 
Specimen Preparation and EM 
 The BoNT/A1, /B, and /E PCs were purified by List Biological Laboratories 
and stored in lyophilized form. The purity of the BoNT/A1 and /B PC at the time of 
purification is indicated by SDS- and Native gels (Fig. 2-1) The samples were 
hydrated with water to yield solutions that were 0.1 mg/mL protein, 20 mM 
HEPES pH 6.8 and 1.25% lactose. The samples were further diluted to 50 µg/mL 
in 20 mM HEPES pH 6.8. Uranyl formate (0.7% wt/vol) was used for conventional 
negative staining as previously described [197]. Images of the BoNT/A, /B, and 
/E progenitor complexes were recorded using a Tecnai F20 electron microscope 
(FEI) equipped with a field emission electron source and operated at an 
acceleration voltage of 200kV. Images were taken under low-dose conditions at a 
magnification of 67,000X using a defocus value of -1.5 μm. Images were 
recorded on a Gatan 4K x 4K CCD camera. Images were converted to mixed 
raster content (mrc) format, and binned by a factor of 2, yielding final images with 
a 3.5 Å/pixel. Particle images of the tilted and untilted BoNT/A, /B, and /E PCs 
were selected and analyzed using SPIDER and the associated display program 
WEB [198]. 
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Fig. 2-1. Analysis of the BoNT/A1 and BoNT/B 16S PCs by SDS- and Native-
PAGE. Lanes 2 and 6 correspond to non-reducing conditions.  Lanes 3 and 7 
correspond to reducing conditions. Lanes 4 and 8 were run in the absence of 
SDS and reductant.   
 
Random Conical Tilt Reconstruction of Negatively Stained BoNT/A, /B, and /E 
PCs  
Micrograph tilt pairs of BoNT/A, /B, and /E PCs were recorded at -55° and 
0°. Particle pairs (BoNT/A-PC: 15,507, BoNT/B-PC: 11,765, and BoNT/E-PC: 
7,792) were selected interactively from both the tilted and untilted images using 
WEB and windowed into 120 x 120-pixel images (3.5 Å/pixel). The untilted 
images were rotationally and translationally aligned and subjected to 10 cycles of 
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multi-reference alignment and K-means classification using no designated initial 
reference.  
 
BoNT/A PC  
Particles were grouped into 4, 5, 25, 50, 75, 100, 200, and 300 classes. 
An initial 3D reconstruction was done using the titled particles (2,550) associated 
with one average from the five group classification (Fig. 2-2, black star). The 
initial 3D reconstruction was done by back-projection using the in-plane rotation 
angles determined by rotational alignment and the preselected tilt angle of 55° 
implemented in the processing package SPIDER. To increase the number of 
particles included in the 3D reconstruction, 5,019 tilted images plus 500 nontilted 
images associated with a class average in the 4-group alignment (Fig. 2-5b) were 
used to further refine the structure using angular refinement in SPIDER. Using a 
FSC = 0.5 criteria the resolution is ~15 Å (Fig. 2-5a); however, the lack of any 
secondary structural details in our map suggests that the resolution more likely 
falls closer to 20 Å.  
 12 classes were selected from the class average of 50 for additional multi-
reference alignment (Fig. 2-6, black dots). A class of 1,114 particles showing a 
‘prong’ orientation (Fig. 2-5c, black star) was used to calculate an initial 3D 
reconstruction by back-projection using the same variables described above. The 
resulting density map was used for the back-projection and angular refinement in 
SPIDER. Ten percent of the untilted particles were included in the data set (115 
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particle images) and angular refinement was repeated. Using a FSC = 0.5 
criteria, the resolution is ~15 Å (Fig. 2-3b); however, examination of structural 
features in the density map suggests the resolution is closer to 20 Å or higher. 
 
 
Fig. 2-2. The BoNT/A1 PC sorted into five classes. The tilted particles 
associated with the average marked with “!” were used for an initial 3D 
reconstruction by back projection of the two-armed complex shown in Fig. 3c. 
Side length of panels, 420 Å.   
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Fig. 2-3. The Fourier shell correlation (FSC) curve for (a) the BoNT/A1 PC 
‘flat’ view reconstruction from Fig. 2-4a, (b) the BoNT/A1 PC ‘prong’ view 
reconstruction from Fig. 2-4b, (c) the BoNT/B reconstruction from Fig. 2-5b, and 
the BoNT/E reconstruction from Fig. 2-6b. 
 
 
BoNT/B PC  
Particles were grouped into 75 classes. 19 classes were selected from the 
class average of 75 for additional multi-reference alignment (Fig 2-11, black 
dots). A class of 2,614 particles (Fig. 2-10a, black star) was used to calculate an 
initial 3D reconstruction by back-projection using the same variables described 
above. The resulting density map was used for the back-projection and angular 
refinement in SPIDER. Ten percent of the untilted particles were included in the 
data set (260 particle images) and angular refinement was repeated. Using a 
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FSC = 0.5 criteria, the resolution is ~15 Å (Fig. 2-3c); however, the lack of any 
secondary structural details in our map suggests that the resolution more likely 
falls closer to 20 Å. The FSC curves for BoNT/A1 and /B PCs do not stay close to 
zero at high resolutions of the graph. We attribute this to artifacts created by the 
large amount of noise present from the flexible third “arm” that could not be 
resolved in the maps. 
 
BoNT/E PC  
Particles were grouped into 10 classes using reference free alignment. 
Four classes were selected as references for an additional round of multi-
reference alignment (Fig. 2-12, black dots). A 3D structure was calculated using 
back-projection from the titled images associated with a class of 692 particles 
from the initial alignment (Fig. 2-12, black star) as an initial model for angular 
refinement of 4,518 tilted images plus 450 nontilted images from a class 
generated in the reference-based alignment (Fig. 2-11, black star). Using a FSC 
= 0.5 criteria, the resolution is ~15 Å (Fig. 2-3d); however, the lack of any 
secondary structural details in our map suggests that the resolution more likely 
falls closer to 20 Å. 
The contouring threshold for all structures was chosen so that the volume 
of the structure was continuous. For display purposes structures were filtered in 
chimera [199] using the “Hide Dust” command to diminish ‘salt and pepper’ noise 
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from the maps by removing single voxels that were unconnected to the main 
volume of the 3D density. 
 
Negative Staining of an Antibody-BoNT/A PC complex  
The 4LCA antibody was purified as previously described [200]. For 
antibody labeling, the proteins were mixed in 1:10 molar ratios and incubated at 
room temperature for 3 h before grid preparation. Grids were prepared as 
described [197]. 403 particles of BoNT/A PC bound to 4LCA were selected 
interactively using WEB and windowed into 150 x 150-pixel images (3.5 Å/pixel). 
The images were rotationally and translationally aligned and subjected to 10 
cycles of multi-reference alignment and K-means classification with no initial 
references designated. 
 
Results 
 
Visualization of BoNT PCs by negative stain EM   
BoNT/A1, /B, and /E PC were adsorbed to carbon-coated glow-discharged 
grids and stained with uranyl formate. EM micrographs revealed monodisperse 
macromolecular assemblies suitable for additional structural analysis for all three 
serotypes. Examination of BoNT/A1 and /B PCs revealed particles composed of 
an ovoid-shaped ‘body’ attached at one side to three extended ‘arms’  (Fig. 2-4b, 
2-4c, 2-5a, 2-10a). Although BoNT/E PC particles shared the same ovoid-shaped 
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body, they lacked the extended arms (Fig. 2-4d). To more closely examine the 
organization of PC complexes, image pairs of BoNT/A1, /B, and /E were 
collected so that the 3D structure of each serotype could be determined using the 
RCT approach.  
 
Fig. 2-4. The BoNT PC is comprised of the neurotoxin and NAPs. (a) The 
BoNT gene locus for representative strains expressing BoNT serotypes /A1, /B, 
and /E. Shown below are the crystal structures for the BoNT/A1-NTNH complex 
(3V0A), the BoNT/D (HA1)2-HA2 trimer (2E4M), and the BoNT/C HA3 trimer 
(4EN6). The structures are colored to match the colors in the gene locus such 
that BoNT/A1 is yellow, NTNH is green, HA1 is blue, HA2 is light blue, and HA3 
is pink.  Two N-acetylgalactosamine binding sites have been identified in the 
structure of HA1/C (3AH2 and 3AJ6), and the sugars have been superimposed 
on the BoNT/D (HA1)2-HA2 trimer structure and depicted as red sticks.   The 
HA3 trimer was crystallized with alpha 2-3-sialyllactose which is depicted in blue 
sticks. (b) The BoNT/A1 PC has three arms projecting away from an ovoid body. 
(c) The BoNT/B PC has a similar structure to the /A1 complex. (d) The BoNT/E 
PC is smaller and resembles the ovoid body seen in the /A1 and /B PCs. (Scale 
bar in images b-d, 50 nm.) 
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The BoNT/A1 PC is a flexible three-armed structure  
Image pairs of grids containing negatively stained BoNT/A1 PC were 
recorded at tilt angles of -55˚ and 0˚. A total of 15,507 pairs of particles were 
selected, and images of the untilted specimens were classified into four class 
averages (Fig. 2-5b). Each class revealed a ‘pincher-like’ feature at the end of 
the arms; however, unlike the raw images that clearly showed particles with three 
extended arms (Fig. 2-4b, 2-5a), only two arms were visible in the averages (Fig. 
2-5b). To attempt to resolve the third arm apparent in our raw images, we 
expanded the number of classes to 50 (Fig. 2-6). 
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Fig. 2-5. The BoNT/A1 PC is a flexible three-arm structure. (a) The three 
arms are evident in a gallery of single particles. (b) When 15,507 particles are 
sorted into four classes only two arms of the PCs three arms are visible. The box 
marked with “!” indicates the “flat” view class used for a 3D reconstruction. (c) 
BoNT/A1 PC class averages obtained by reference-based alignment. The box 
marked with “!” indicates the class used for an alternate “prong” view 3D 
reconstruction. Side length of panels, 420 Å. 
 
  As expected, when the particles were sorted into a larger number of 
classes, we began to observe averages containing three arms, although one of 
the three arms was always less resolved than the other two. In addition, from this 
group of 50 class averages we noticed that the particles adsorb to the carbon film 
in two distinct orientations.  One is a ‘flat’ orientation that is composed of an ovoid 
body with two well-defined arms (Fig. 2-6, black star) and the other is a ‘prong’ 
orientation that contains an ovoid body with only one well-defined arm (Fig. 2-6, 
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white star). A majority of the averages (containing ~90% of the total particles) are 
in the ‘flat’ orientation, while the remaining averages (containing ~10% of the total 
particles) are in the ‘prong’ orientation. To generate better resolved ‘prong’ 
averages we selected 12 class averages from our analysis using 50 classes (Fig. 
2-6, black dots) and used these for a further round of reference-based alignment 
(Fig. 2-5c).  
 
 
Fig. 2-6. Classes of BoNT/A1 PC three-armed species begin to emerge if 
the class size is expanded to 50. The two preferred orientations of the PC on 
the grid surface are indicated by either a black “!” (‘flat’ view) or by a white “!” 
(‘prong’ view.). Boxes marked with “"” indicate classes selected for the 
referenced-based alignment shown in Fig. 2. Side length of panels, 420 Å. 
 
 
In an effort to generate averages containing an ovoid body with three well–
resolved arms, the particles were sorted into groups of 100, 200, or 300 classes. 
When divided into 300 classes, the third arm is visible in a third of the class 
averages; however each class contains only a small number of particles making 
the averages noisy and not suitable for 3D reconstructions. When comparing 
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distinct classes composed of particles either in the ‘flat’ or ‘prong’ view, it is clear 
there is significant flexibility in the orientation of the pinchers relative to the arms 
and the orientation of the arms relative to the ovoid body and suggests that 
flexibility is an intrinsic feature of the BoNT/A1 PC. 
The conformational heterogeneity made it difficult to generate well-populated 
classes containing three well-resolved arms. Therefore, we opted to calculate two 
3D reconstructions using tilted images either associated with a class average in 
the ‘flat’ orientation (Fig. 2-5a, black star) or associated with a class average in 
the ‘prong” orientation (Fig. 2-5b, black star) using the RCT approach. Both 
reconstructions led to well-defined 3D structures that contained features seen in 
the 2D averages (Fig. 2-7a and b), suggesting that the 3D reconstructions were 
successful. The overall features of the structure generated from the ‘flat-view’ 
particles (Fig. 2-7a) are better resolved than the features seen in the structure 
generated from the ‘prong-view’ particles (Fig. 2-7b). This is due to the larger 
number of images in the ‘flat’ projection average (5,019) than in the “prong” 
projection average (1,114). We aligned our two 3D reconstructions (‘flat’ and 
‘prong’ structures) to produce a 3D model of the three-armed BoNT/A1 PC (Fig. 
2-7c). Our model shows a triangular plate and V-shaped pinchers assembled at 
one end of an ovoid-shaped body and agrees well with the three-armed complex 
we observe at the single particle level in our EM micrographs (Fig. 2-5a).  
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Figure 2-7. The molecular organization of the BoNT/A1 PC. (a) Surface 
representations of 3D reconstructions of the BoNT/A1 “flat” view and (b) “prong” 
view in negative stain. (c) An alignment of the two BoNT/A1 3D views reproduces 
the three-armed complex observed in our EM micrographs.  (d) Crystal structures 
(from Fig. 1a) placed into a mesh representation of the “flat” view reconstruction. 
(e) Class averages of the BoNT/A1 PC with an antibody specific to the 
neurotoxin’s catalytic domain reveal specific binding at the end of the ovoid body 
furthest away from the HA proteins (black arrows). The scale bars for images a-d 
correspond to 50 Å. 
 
The observed geometric features of ovoid body, triangular plate, and V-
shape pinchers correlate with the shapes observed in the high-resolution crystal 
structures of the BoNT/A1-NTNH complex [47], the BoNT/C HA3 trimer [193], 
and the BoNT/D (HA1)2-HA2 trimer [195], respectively (Fig. 2-4a, 2-7d). While 
the EM structure is not at a resolution that would permit a detailed docking 
analysis, the BoNT/D (HA1)2-HA2 trimer could easily be placed into the ‘pinchers’ 
and the BoNT/C HA3 trimer was placed into the triangular plate of the electron 
density map.  The orientation of the BoNT/C HA3 trimer was guided by the fact 
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that the BoNT/C HA3 proteins, when viewed from the side, form a shallow ‘W’ 
shape consistent with features we observe in our structure (Fig. 2-8). While it was 
clear that the remaining ovoid body corresponded to the BoNT/A1-NTNH 
complex, there were two possible ways to orient the crystal structure of the 
complex within our density map.  The genes encoding BoNT/A1 and NTNH are 
thought to have emerged from a gene duplication event, and the structures of 
these two molecules are similar [47].  In one scenario, the BoNT/A1 LC would 
make contact with the HA3 triangular plate while the LC-equivalent of the NTNH 
(nLC) would form the base of the ovoid body.  In the other scenario, the nLC 
would be in contact with the HA3 trimer while the BoNT LC was at the distal end 
of the complex. To distinguish between these two possibilities, we labeled the PC 
with a BoNT/A1 LC specific monoclonal antibody [200]. We observed consistent 
and efficient labeling of the distal end of the ovoid body (Fig. 2-7e, 2-9) thus 
confirming the placement where the nLC interacts with the HA3 trimer.  The 
placement of the crystal structures (Fig. 2-4a) into the two arm and three arm 
structures of the BoNT/A1 PC is shown in Figures 2-7d and 2-10, respectively. 
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Fig. 2-8. Orienting the HA3 trimer in the PC structure. (a) When viewed from 
the side, the HA3 trimer adopts either a ‘M’ or ‘W’ shape. (b) When the electron 
density is oriented with the pinchers at the top and the ovoid body at the bottom, 
the HA3 trimer can be confidently placed into the triangular plate in the ‘W’ 
orientation. The scale bar corresponds to 50 Å. 
 
 
 
Fig. 2-9. Labeling the BoNT/A1 PC with an antibody against the 
neurotoxin’s catalytic domain. The BoNT/A1 complex was incubated with 
4LCA and visualized by negative stain EM. A gallery of labeled single particle 
BoNT/A1 PCs is shown. Side length of panels, 525 Å. 
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The BoNT/B PC has a similar structure to the BoNT/A1 PC  
 
Negative stain EM micrographs of the BoNT/B PC show a macromolecular 
assembly that closely resembles the BoNT/A1 PC (Fig. 2-4c, 2-10a) although the 
sample appeared to be more heterogeneous with PC assembly or disassembly 
intermediates evident as single particles. Image pairs were collected at tilt angles 
of -55° and 0° and a total of 11,765 particles were selected. The untilted particles 
were initially sorted into 75 classes and averaged (Fig. 2-11).  In addition to a 
‘flat’ view, similar to what we observed with the BoNT/A1 PC, we observed 
complexes where one or more of the components seemed to be missing (Fig. 2-
11, colored boxes).  19 classes representing the range of complexes observed in 
the sample were selected for multi-reference alignment (Fig. 2-11, black dots). A 
class containing 2,614 particles that clearly showed the main body with two of the 
three arms well-resolved was selected for 3D reconstruction (Fig. 2-10b, black 
star). The face view of the density map closely resembles the projection map 
suggesting a successful 3D reconstruction (Fig. 2-10c). The overall BoNT/B PC 
reconstruction resembles that of the BoNT/A1 PC. Independent placement of the 
crystal structures (Fig. 2-10d) suggests that the BoNT/A1 and BoNT /B PCs have 
a similar structural organization. 
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Fig. 2-10. The BoNT/B PC has a similar structure to the BoNT/A1 PC. (a) The 
three arms are evident in a gallery of single particles. (b) BoNT/B PC class 
averages obtained by reference-based alignment and classification.  The box 
marked with “!” indicates the class used for the 3D reconstruction shown in c 
and d. Side length of panels in a and b, 420 Å. (c) Surface representation of the 
3D reconstruction of BoNT/B PC. (d) Crystal structures (from Fig. 2-2a) placed 
into a mesh representation of the BoNT/B PC. The scale bars in panels c and d 
correspond to 50 Å. 
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Fig. 2-11. The BoNT/B PC sample contains assembly/disassembly 
intermediates. Boxes marked with “"” indicate classes selected for the 
referenced-based alignment shown in Fig. 4a. The outlined boxes show different 
assembly/disassembly states in the sample: red = no HA1/HA2 pinchers, yellow 
= one pair of pinchers, orange = two pairs of pinchers, blue = three pairs of 
pinchers, and green = the NAP assembly without the neurotoxin. Many of the 
classes with two pairs of pinchers (including the one in orange) also include 
individual particles with 3 pinchers where the third pincher has not been resolved 
due to flexibility. Side length of panels, 420 Å. 
 
 
The BoNT/E PC resembles the ovoid body observed in the BoNT/A1 and BoNT/B 
complexes  
Negative stain EM micrographs of the BoNT/E PC show a macromolecular 
assembly that closely resembles the ovoid-shaped body observed in the 
BoNT/A1 and BoNT/B PCs (Fig. 2-4d). The smaller particles are consistent with 
the description of BoNT/E PC as a 12S complex and the fact that the BoNT/E 
gene locus does not have the HA operon. Image pairs were collected at tilt 
angles of -55° and 0° and a total of 7,792 particles were selected. The untilted 
particles were sorted and averaged in 10 classes (Fig. 2-12) and reveal classes 
resembling the ovoid body of the BoNT/A1-NTNH/A1 complex and classes that 
likely represent dissociated BoNT/E or NTNH/E monomers.  Four classes were 
selected for multi-reference alignment (Fig. 2-12, black dots). A referenced-based 
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alignment class containing 4,518 particles that clearly showed the ovoid body 
was selected for a 3D reconstruction (Fig. 2-13a, black star). The face view of the 
density map resembles the projection map suggesting a successful 3D 
reconstruction (Fig. 2-13b).  We could not unambiguously place the BoNT/A1 
12S PC crystal structure into the 3D reconstruction of the BoNT/E 12S PC, 
because we lacked an antibody that could be used to determine which end 
corresponded to the BoNT/E LC and which end corresponded to the nLC of 
NTNH/E.  However, the symmetry of the BoNT/E 12S structure (Fig. 2-13b) and 
the similarity with the ovoid bodies observed in the structures of the BoNT/A1 
(Fig. 2-7a, 2-7c) and BoNT/B (Fig. 2-10c) PCs suggest that BoNT/E is capable of 
binding NTNH/E in a conformation similar to how BoNT/A1 binds NTNH/A.  
 
Fig. 2-12. A BoNT/E PC class average of 10 shows the two-protein complex 
and individual proteins likely from the complex. Boxes marked with “"” 
indicate classes selected for the referenced-based alignment shown in Fig. 5a. 
Side length of panels, 420 Å.   
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Fig. 2-13. The BoNT/E PC resembles the ovoid body observed in the /A1 
and /B PCs. (a) BoNT/E class averages obtained by reference-based alignment 
and classification. The box marked with “!” indicates the class used for the 3D 
reconstruction shown in b. Side length of panels, 420 Å. (b) Surface 
representation of the 3D reconstruction of the BoNT/E PC. The scale bar 
corresponds to 50 Å. 
 
Discussion 
Our study provides the first 3-D descriptions of the BoNT/A1 16S PC, the 
BoNT/B 16S PC and the BoNT/E 12S PC. Our data suggest that the BoNT/A1 
PC adopts a flexible three-armed structure with a BoNT:NTNH:HA1:HA2:HA3 
stoichiometry of 1:1:6:3:3. A BoNT/A1 PC with this stoichiometry has a calculated 
MW of ~760 kDa, halfway between the estimates provided by centrifugation 
studies (500 kDa for the 16S PC and 900 kDa for the 19S PC).  The BoNT/A1 PC 
structure (Fig. 2-7a and 2-7d) resembles the BoNT/B PC structure (Fig. 2-10c 
and 2-10d) as well as the model put forth by Hasegawa et al. based on electron 
micrographs of the BoNT/D PC [195]. We interpret this similarity to mean that the 
BoNT/A1 PC structure is in the 16S form. No evidence of dimers or larger 
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complexes was observed in our analysis of the BoNT/A1 PC sample and could 
reflect dissociation of the 19S PC at low concentrations [173].  
In addition to dissociation of the 19S complex, there are reports that 
document the reversible assembly and disassembly of components in the smaller 
complexes [201,202].  We observed this in our analysis of the BoNT/B PC 
sample which had structures resembling the 1) BoNT-NTNH ovoid body 2) 
BoNT-NTNH bound to an HA3 trimer, or 3) BoNT-NTNH-(HA3)3 associated with 
either 1, 2, or 3 (HA1)2-HA2 assemblies (Fig. 2-10a).  In vitro, the complexes are 
known to be pH-sensitive, with disassembly occurring at pH ≥ 7.5 [171,172,203].  
What occurs in the context of the small intestine is less clear.  Some reports 
suggest that the BoNT will be fully released from the NAPs in the small intestine 
(the pH of the duodenum is ~ 7.0), and there is evidence documenting the 
capacity of the BoNT to cross the epithelial barrier in the absence of the NAPs 
[77,176,177].  Experiments in pH 7 rat intestinal juices however, indicate that the 
PC does not dissociate [180].  Whole PCs are capable of being absorbed from 
the intestine into the lymphatics in a rat ligated duodenum loop assay [181], 
consistent with the hypothesis that the NAPs contribute to absorption in the 
intestine [179].   
There are now strong data to support the role of NTNH in protecting the 
BoNT from acidic and proteolytic degradation in the digestive tract [47]. These 
data are consistent with the 10-20x enhancement in oral MLD50 when the 12S PC 
is compared to the neurotoxin alone [62].  We know that the addition of the HA 
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proteins to form the larger 16S PC enhances the oral MLD50 even further (the 
BoNT/A1 16S PC is 1.6x more potent than the BoNT/A1 12S PC and the BoNT/B 
16S PC is 733x more potent than the BoNT/B 12S PC) [62].  Our structures of 
the BoNT/A1 and BoNT/B 16S PCs indicate that the HAs have no direct contact 
with the BoNT’s, and suggest that the HAs do not play a ‘protective’ role but 
instead contribute to intestinal absorption.  
The HA proteins could contribute to intestinal absorption by enhancing 
adhesion of the BoNT PC to mucins or the cell surface, disrupting the epithelial 
barrier, or by facilitating transcytosis [179].  Consistent with the capacity of the 
HAs to agglutinate red blood cells, the HAs are known to bind a variety of 
sialylated oligosaccharides.  Binding studies using a glycoconjugate microarray 
indicate that HA3/C preferentially recognizes a2-3- and a2-6 sialylated sugars, 
and the binding site for these sugars has been elucidated by X-ray 
crystallography [186] (Fig. 2-14b). N-acetylneuraminic acid, N-
acetylgalactosamine, and galactose block the binding of HA1/C to mucins, and 
crystallography has revealed a common site where these sugars can bind.  
Galactose is also capable of binding a second site on HA1/C [185].  These 
binding sites could represent points of contacts between the BoNT/C PC and 
mucins, glycolipids, or glycoproteins within the intestine.  While co-crystal 
structures of the HAs from /A1 and /B strains with sugars are not yet available, 
the HA molecules share a high degree of sequence identity at the amino acid 
level suggesting that the sugar binding sites could be conserved.  Importantly, 
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each binding site is accessible in the models we have generated of the BoNT/A1 
and BoNT/B 16S PC (Fig. 2-14a, 2-14d, 2-14e).   
The BoNT’s are also known to interact with sialic acid containing sugars, and 
the interaction with GT1b gangliosides are known to be important in the dual-
receptor model where BoNT uses a ganglioside and protein to mediate 
interaction with the neuronal cell surface [204]. The GT1b binding pocket has been 
defined by X-ray crystallography [205] and is accessible in the context of the 16S 
PC structure (Fig. 2-14c, 2-14e).  Since GT1b gangliosides are present in epithelial 
cells of the small intestine, this interaction could contribute to adhesion as well.  
SV2 and synaptotagmin are, respectively, known protein receptors for BoNT/A1 
and BoNT/B on neurons [117,154,206] but the relevance of these receptors in 
the intestine is not clear.  We note that the SytII binding site for BoNT/B [121,155] 
is fully accessible in the context of the 16S PC structure (Fig. 2-14c, 2-17e).   
Our structural studies have shown that the BoNT/A1 and BoNT/B 16S PCs 
are flexible three-armed structures.   The fact that the HA proteins do not interact 
directly with the BoNT suggests that they are not required for toxin protection but 
may be important for multivalent binding interactions with mucin and/or the 
epithelial cell surface. It is tempting to speculate that the flexibility we observed in 
the analysis of the BoNT/A1 PC allows the complex to effectively ‘sample’ the 
intestinal surface and improve the chances of absorption of the toxin prior to high 
pH dissociation of the complex and proteolytic degradation of the neurotoxin.  
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The potential to harness the HA proteins as a platform to increase intestinal 
absorption in other applications is an exciting possibility for future studies. 
 
 
Fig. 2-14. 16S PCs have multiple sugar binding sites. 16S PCs have multiple 
sugar binding sites. (a) Two N-acetylgalactosamine binding sites have been 
identified in the structure of HA1/C (3AH2 and 3AJ6), and the sugars have been 
superimposed on the BoNT/D (HA1)2-HA2 trimer structure (blue) and depicted as 
red sticks.   (b) The HA3 trimer (pink) was crystallized with alpha 2-3-sialyllactose 
which is depicted in red sticks. (c) The GT1b binding site (with GT1b shown in red 
sticks) is located between BoNT/A1 (gold) and NTNH (green).  Superposition of 
the BoNT/B HCR-SytII structure (2NM1) onto the BoNT/A1 HCR suggests that 
the SytII binding site will be accessible in the BoNT/B PC structure (SytII depicted 
as a red a-helix).  (d) A model of a ‘flat’ view BoNT/A1 PC shown with three arms. 
(e) The BoNT PC rotated 180 degrees to the ‘prong’ view reveals the 
accessibility of the GT1b binding site and the SytII binding site. 
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Chapter III 
 
ANALYSIS OF TETANUS HOLOTOXIN BY ELECTRON MICROSCOPY 
REVEALS NEW INSIGHT INTO ITS STRUCTURAL ORGANIZATION 
 
Introduction 
 Tetanus neurotoxin (TeNT) is the causative agent of the debilitating 
spastic paralysis known as tetanus. TeNT is only produced by the anaerobic 
bacteria Clostridium tetani, and is considered the second most potent toxin on 
the planet after botulinum neurotoxin (BoNT) [27]. C. tetani form spores when 
growth conditions become unfavorable. These spores, which can remain dormant 
for long periods of time, are widely distributed in the environment and are often 
found in soil samples [207]. Tetanus can develop after a wound becomes 
contaminated with C. tetani spores. Wounds that offer anaerobic conditions allow 
the spores to germinate into toxin producing bacteria. TeNT is synthesized as a 
single-chain polypeptide that is proteolytically cleaved to form an active dichain 
molecule [208]. The chains consist of a 50 kDa light chain (LC) and a 100 kDa 
heavy chain (HC) that remain linked by an interchain disulfide bond. The toxin 
has three ~50 kDa functional domains: binding, translocation, and catalytic. 
Nicked TeNT has a N-terminal LC linked to the HC, which contains the N-
terminal translocation domain (HCN) and C-terminal binding domain (HCC).  The 
LC is the catalytic domain of the toxin and functions as a zinc protease that 
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targets and selectively cleaves the vesicle associated SNARE protein 
synaptobrevin [144,145].  
After entry into the blood stream, TeNT initially targets the presynaptic 
membrane of peripheral nerve terminals [65]. The HCN has two carbohydrate 
binding pockets: a lactose-binding site and a sialic acid binding site which has 
been shown to bind multiple glycosphingolipids [115,125,209] that are enriched 
on peripheral nerve terminals. These gangliosides function as dual receptors that 
bind TeNT HCC with high affinity [28,125,210]. Upon binding, TeNT undergoes 
clathrin-dependent, epsin-1 independent endocytosis [128] which allows the toxin 
to be sorted into an endosomal vesicle that is not acidified [129,133]. The vesicle 
containing TeNT continues to motor neurons in the spinal cord via a fast axonal 
retrograde transport that requires F-actin, microtubules, and related motor 
proteins [131,132]. These findings suggest that this particular endocytic route 
prevents HCN membrane insertion and LC release into the cytoplasm thus 
allowing TeNT to remain intact during its transport [116]. TeNT then crosses 
intersynaptic space between peripheral motor neurons and inhibitory 
interneurons. The toxin binds a receptor on the presynaptic membrane of the 
inhibitory interneuron. The receptors identity is still a matter of debate [124,211]. 
TeNT enters the neuron via synaptic vesicle and as the pH of this vesicle lowers 
the conformation of the toxin changes. The HCN insertion into the endosomal 
membrane triggers the release of the LC into the neuronal cell cytosol [143]. 
Here, the TeNT LC selectively targets and cleaves synaptobrevin, a vesicle 
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associated protein required for the docking and membrane fusion of 
neurotransmitter synaptic vesicles. Cleavage of synaptobrevin prevents the 
release of the inhibitory neurotransmitters γ-aminobutyric acid (GABA) and 
glycine resulting in the uncontrollable motor reflex responses to sensory 
stimulation that characterize the spastic paralysis of tetanus [212]. 
TeNT has a ~65% sequence identity with the BoNT serotypes [156] and 
while the debilitating paralysis associated with TeNT and BoNT are very different, 
the two proteins share many structural similarities. Both toxins are activated by 
protease mediated nicking into dichain peptides that remain linked by a disulfide 
bridge. Furthermore, the heavy and light chains of each toxin are organized into 
similar functional domains. The crystal structures for the three BoNT serotypes 
associated with human disease (types A, B, and E) have been determined [146–
148]. Interestingly, the individual domains for each of the BoNTs have 
comparable structures though the overall domain organization for the toxins 
varies. The three domains of BoNT/A and /B are organized such that the catalytic 
and binding domains are located on either side of the translocation domain. The 
structure of BoNT/E is unique in that the binding and catalytic domains are 
located on the same side of the translocation domain (Fig. 3-4b).  
The structure of the tetanus holotoxin is currently unknown however, the 
structures for the TeNT binding and catalytic domains have been determined 
individually [112,145,149,151] and are similar to their BoNT counterparts. The 
holotoxin has been crystallized [213–215] but not for the purpose of collecting X-
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ray diffraction data. TeNT holotoxin secondary structures have been studied 
using Fourier transform infrared spectroscopy and circular dichroism [216,217]. A 
three-dimensional (3D) analysis of the holotoxin was performed using electron 
crystallography of two-dimensional (2D) crystals bound to a lipid monolayer [218]. 
The resulting structure is low resolution and described as “mitten shaped” with a 
“palm” separated from the “thumb” by a pronounced groove. 
Despite these structural studies, the organization of TeNTs three domains, 
how they relate to one another, or how its structure compares to other BoNTs is 
unknown. Here, we present 2D images of the TeNT holotoxin generated by 
negative stain electron microscopy (EM) and single particle averaging. The 
subsequent TeNT images were then compared to the BoNT/A and /E structures. 
Our analysis shows that TeNT does not undergo a discernible conformation 
change upon activation and that its holotoxin structure is more similar to BoNT/E 
than /A. 
 
METHODS 
 
Protein Expression and Purification 
 Dr. Michael Baldwin, at the University of Missouri, generously provided the 
wild type TeNT gene in a pET28 expression plasmid. TeNT was recombinantly 
expressed in E. coli BL21-AI cells. Transformed cells were grown in 5 mL luria 
broth (LB) subculture containing 50mg/L kanamycin at 37°C for ~3 h. When 
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subculture was slightly turbid 200 μL was plated as a lawn on LB agar plates 
supplemented with kanamycin and grown overnight at 37°C. The bacterial lawn 
was gently suspended in 10 mL LB and transferred to a 2L flask containing LB 
supplemented with kanamycin. The cultures were placed at 30°C and 220 rpm. 
When the cultures reached OD600 = 0.6 expression was induced by the addition 
of L-Arabinose to a final concentration of 0.2% wt/vol and IPTG to a final 
concentration of 0.75 mM. Incubation was continued overnight at 16° and 220 
rpm. After ~18 h the cells were harvested by centrifugation and resuspended in 
50 mM NaCl, 30 mM Tris, pH 8.0. Following French Press lysis, the lysates were 
centrifuged at 39,000xg for 30 min. Protein was purified from the supernatant by 
Ni2+ affinity in 50 mM NaCl, 30 mM Tris, pH 8.0 buffer. TeNT eluted from the Ni2+ 
column with 200 mM imidazole.  Ion exchange chromatography was used with 
30mM Tris, pH 8.0 buffer that ranged from zero NaCl content to 500 mM. Gel 
filtration chromatography was the final purification step and was run in 30 mM 
Tris pH, 8.0, 100 mM NaCl buffer.  
Trypsin digestion was used to recapitulate the activated, nicked form of 
the toxin. TeNT at a concentration of I mg/mL was digested overnight at 4°C with 
1 mg/mL trypsin at 1:1000 (Fig. 3-1). This produced dichain molecules that could 
be separated by disulfide bond reduction (Fig. 3-1).  
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Fig. 3-1. The ideal trypsin to TeNT ratio to obtain activated toxin is 1:1000. 
Inactive TeNT was treated with varying concentrations of trypsin to determine the 
best enzyme/protein ratio. A protein molecular weight ladder is shown on the left. 
1a: no trypsin, no DTT, 1b: no trypsin, w/DTT, 2a: 1:10, no DTT, 2b: 1:10 w/DTT, 
3a: 1:100, no DTT, 3b: 1:100 w/DTT, 4a: 1:1000, no DTT, 4b: 1:1000 w/DTT, 5a: 
1:10,000, no DTT, 5b: 1:10,000 w/DTT. Red box indicates good digestion of 
TeNT; the disulfide bond linking the heavy and light chains is reduced with DTT. 
 
Specimen Preparation and EM 
 Uranyl formate (0.7% wt/vol) was used for conventional negative staining 
as previously described [197]. Images of un-nicked and nicked forms of TeNT 
were recorded using a Tecnai F20 electron microscope (FEI) equipped with a 
field emission electron source and operated at an acceleration voltage of 200kV. 
Images were taken under low-dose conditions at a magnification of 67,000X 
using a defocus value of -1.5 μm. Images were recorded on a Gatan 4K x 4K 
CCD camera. Images were converted to mixed raster content (mrc) format, and 
binned by a factor of 2, yielding final images with a 3.5 Å/pixel. Particle images of 
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the un-nicked and nicked forms of TeNT were selected using EMAN [219] and 
analyzed using SPIDER and the associated display program WEB [198]. 
 
Un-nicked TeNT and nicked TeNT Processing 
Single particles of each toxin type were aligned and classified using the 
software Boxer [219] and Spider [220]. 
 
Crystal Structure Filtering 
 The crystal structures for BoNT/A (pdb: 3BTA, [146]) and BoNT/E 
(pdb:3FFZ, [148]) were selected for resolution-filtering. Their pdb coordinate files 
were converted into a mixed raster content (mrc) format using SPARX (single 
particle analysis for resolution extension) [221] with an Angstrom to pixel ratio of 
3.5 and a box size of 72. The resulting density map was resolution-filtered to 
approximately 40 Å using EMAN2 [222] and was visualized using CHIMERA 
[199]. 
 
Results 
 
The activation of TeNT does not induce an observable conformational change  
 
 Images were collected of both the inactive (un-nicked) form of TeNT and 
the active (nicked) form. A total of 5,133 inactive particles and 5,064 activated 
particles were selected for class averages. The un-nicked and nicked TeNT 
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particles were each sorted into fifteen class averages (Fig. 3-2a, 3-2b) using 
reference free alignment. The two forms of TeNT appeared to have similar 
structures. Both forms of the toxin adopted a “J” shape that could be grouped in 
three predominant orientations depending on their interaction with the grid 
surface.  Four globular domains were observed within the “J” shaped molecules. 
Interestingly, no observable conformational changes between the un-nicked and 
nicked toxins could be detected at the EM level of resolution. 
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Fig. 3-2. Inactive TeNT and activated TeNT have similar structures by EM. 
(a) 5,133 un-nicked TeNT particles were aligned and sorted into 15 class 
averages. (b) 5,064 nicked TeNT particles were aligned and sorted into 15 class 
averages. There is no observable conformation change (by EM) between inactive 
and trypsin activated TeNT. The majority of class averages for both toxin types 
contain three variations of “J” shaped molecules with four globular domains 
visible. Side length of panels, 240 Å. 
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Reference–based alignments were performed to verify that there was no 
distinct conformation change between the two toxin types. Three representative 
classes were selected from the un-nicked and nicked toxins (Fig. 3-2a, 3-2b, 
black dots). The three un-nicked classes were used for referenced-based 
alignments against the entire population of nicked particles (Fig. 3-3a). 
Conversely, the three nicked classes were used against all of the un-nicked 
particles (Fig. 3-3a). Conformational differences between the two toxin types 
would, in theory, be more pronounced by aligning the entire population of one 
toxin type against three references representing the other toxin type. The un-
nicked population of particles (Fig. 3-3b) and the nicked population (Fig. 3-3c) 
aligned reasonably well into either set of input references (3-3a). We observed 
that there were no significant differences in structure between the two 
populations of toxin particles, suggesting that the activation of TeNT does not 
induce a dramatic conformational change in the molecule. A higher resolution 
(crystal) structure of the holotoxin could reveal more subtle changes in the 
structure. 
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Fig. 3-3. Referenced-based alignments to compare the structures of the 
two forms of TeNT. (a) The three un-nicked input references are to the left while 
the three nicked references are to the right. (b) A reference-based alignment 
using the six references from (a) against 5,133 un-nicked particles. (c) A 
reference-based alignment using the six references from (a) against 5,064 nicked 
particles. 
 
Negative stain EM averages of TeNT more closely resemble EM averages of 
BoNT/E than BoNT/A 
 
 
 The high resolution structure of BoNT/A [146] revealed the structural 
organization of its three domains. In it the binding and catalytic domains flank the 
translocation domain (Fig. 3-4a). Interestingly, the structure of BoNT/B [148] was 
also found to also have this “flanking” orientation for its domains (Fig. 3-4b). 
Before the crystal structure of BoNT/E was determined in 2009 [148] analysis of 
its structure had been investigated using negative stain EM and single particle 
averaging by Fischer et al. [223]. Work done by Fischer et al. used the structural 
	  	   75	  
organization of type /A to guide their assessment of the type /E structure. Both 
toxins were negatively stained and sorted into class averages. The BoNT/A 
classes clearly illustrated the same organization as its crystal structure (Fig. 3-4a, 
Fig. 3-5a). The BoNT/E class averages provided the first insight that the /E toxin 
had a unique organization as compared to types /A and /B (Fig. 3-5b).  
 As stated earlier, the holotoxin structure for TeNT is unknown but crystal 
structures for its binding [149] (Fig. 3-4c) and catalytic [145](Fig. 3-4d) domains 
have been determined. These TeNT domains are very similar in structure to their 
known BoNT homologs. 
 
 
Fig. 3-4. Crystal structures for BoNT/A, BoNT/E, and two TeNT domains. For 
each toxin type the domains are colored: binding=beige, translocation=green, 
and catalytic=blue. (a) The translocation domain of BoNT/A is flanked by its 
binding and catalytic domains. (b) The BoNT/E structure has the binding and 
catalytic domains on one side of the translocation domain. (c) The TeNT binding  
and (d) catalytic domains have similar folds as their BoNT homologs. 
 
 We were interested to see if more structural insight of TeNT could be 
gained utilizing an EM approach similar to the one used for BoNT/E. We 
compared class averages of BoNT types /A and /E generated by Fischer et al. 
(Fig. 3-5a and b) to our classes of active form TeNT (Fig. 3-5c). The two 
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structural organizations of /A and /E are evident by negative stain. Our TeNT 
class averages did not appear to adopt an /A –like structure and more closely 
resembled that of type /E. We next filtered both the /A and /E crystal structures to 
~40 Å and placed them in similar orientations as their representative class 
averages (Fig. 3-5d, e, and h). Both filtered structures were rotated over an array 
of angles. It was of interest to see if either the filtered /A or /E would generate a 
“J” shaped structure. The filtered /A structure formed some what of a “J” shaped 
structure when it was rotated to its side (Fig. 3-5g), but on an EM grid with 
negative stain this orientation would likely not be preferred. The /E filtered 
structure however could make J” shaped structures when rotated (Fig. 3-5f). The 
two TeNT domain crystal structures were aligned with the /E crystal structure in 
an attempt to predict how the domains of TeNT may be arranged (Fig. 3-5i). In 
this model the TeNT binding domain forms the “lower loop of the J” while the 
cross at the top of the “J” shape has the catalytic domain on the left and the 
translocation domain on the right. We hypothesize that the helices of the 
translocation domain are compressed behind the structure and interacting with 
the grid surface. 
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Fig. 3-5. TeNT resembles the organization of BoNT/E more than BoNT/A. (a) 
and (b) 2D class averages of BoNT/A and BoNT/E from Fischer et al. [223]. (c) 
2D class average of nicked TeNT.  (d) BoNT/A filtered to a resolution of ~ 40 A. 
(e) BoNT/E filtered to a resolution of ~ 40 A. (f) Filtered BoNT/E can be rotated to 
form the “J” shape observed in the TeNT 2D averages. (g) Filtered BoNT/A does 
not form a satisfactory “J” shape after rotation. (h) BoNT/E crystal structure in 
same orientation as (b) and (e). (i) TeNT catalytic domain (blue) and binding 
domain (gold) are aligned with BoNT/E structure seen in (f). 
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Discussion 
 Given the significant sequence homology between TeNT and the BoNTs it 
is not surprising that the structures of the two crystallized domains from TeNT so 
closely resemble their BoNT homologs. BoNT/E has a unique organization 
compared to the other serotypes (/A and /B) that cause human botulism. The 
significance of this structural difference in /E is still being explored. One 
hypothesis is that the consolidation of the domains to one side of the 
translocation domain may contribute to a faster release of the catalytic domain 
into the neuronal cytosol [224].  
 Here we present analysis of the TeNT holotoxin by negative stain EM and 
single particle averaging. We have observed that there is no discernable 
difference in toxin conformation after being activated with trypsin cleavage and 
that the TeNT molecules have a “J” shape. When our 2D averages of activated 
TeNT were compared to those of BoNT/A and /E we saw that of the two known 
BoNT structures TeNT was more closely related to /E. To explore this further, the 
two BoNT structures were filtered to approximately 40 A. These structures were 
each studied from an array of rotational angles in an effort to determine if either 
filtered structure could make a “J” shape. BoNT/A did not make a satisfactory “J” 
shape while the filtered /E molecule did. The structures of the two TeNT domains 
were aligned with their /E homologs and showed that TeNT likely has an 
organization more like /E. 
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 To confirm this hypothesis, we propose to try some labeling techniques. 
Unfortunately, there are limited monoclonal antibodies for TeNT available 
commercially. Our recombinant TeNT construct is engineered with a N-terminal 
6xHis tag, however, that could potentially be labeled with gold nanoparticles 
designed to interact with the His tag. An alternative approach to evaluate the 
structure would be to try generating a 3D reconstruction of TeNT using the 
random conical tilt approach [196]. This may be challenging to accomplish due 
the small size of the toxin. Lastly, and ideally, we would like to determine the 
high-resolution structure of TeNT. Crystallization trials are currently underway 
and will hopefully yield conclusive evidence that the TeNT holotoxin structure is 
similar to BoNT/E.  
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 BoNT and TeNT and their associated diseases continue to sicken people 
around the world. The potential weaponization of BoNT and its use in an act of 
bioterrorism is considered a real threat to society. Remarkably, these toxins are 
also appreciated for their clinical applications to treat many dystonias of the 
musculature and for their unique mechanisms that researchers have used to 
better understand the function of the brain. Previous structural work on the CNTs 
has provided additional insight on the function of the toxins and has helped better 
explain their mechanisms for pathogenesis. In my thesis work, I have shown the 
molecular organization for the accessory proteins that interact with BoNT to form 
progenitor complexes and I have also determined low-resolution structures of the 
TeNT holotoxin 
 In Chapter II, I have presented 3D reconstructions of the three BoNT 
serotypes associated with human botulism using negative stain EM, single 
particle averaging, and the random conical tilt (RCT) method. Using these 
techniques I was able to successfully model the molecular organization for BoNT 
serotypes /A and /B. Both toxins were observed as ovoid shaped bodies that had 
an assembly of three arms with pincher shapes attached at a distal end. Using 
RCT, I was able to produce 3D density maps of the toxins and fit in crystal 
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structures of accessory proteins that are known to be a part of the complex. This 
was the first visualization of these complexes whose structure had been a matter 
of debate for quite some time. I noticed a large degree of flexibility in the /A 
complex, especially in the arm assembly at the end. I was able to explore this by 
producing movies made from many individual classes. These movies showed the 
degree of flexibility these complexes could have and helped us conceptualize 
how the structure could interact with the epithelial cells in the small intestine. 
BoNT/E was observed as an ovoid body, which was consistent with what was 
known about its accessory proteins. While I was unable to successfully use my 
3D reconstruction to predict its molecular assembly it was still the first time the 
BoNT/E complex was visualized. 
 In Chapter III, I describe characterization of the EM the structure of the 
TeNT holotoxin. Two of the toxins three domains have had their structures 
determined but the overall architecture of all three domains is not known. Using 
negative stain EM and single particle averaging. I was able to produce novel 
images of the holotoxin. With this study, I demonstrated that inactive TeNT and 
TeNT activated by proteolytic cleavage were similar in structure, and no 
discernable conformational changes occurred as a result of TeNT nicking. I went 
on to compare my nicked TeNT 2D averages with those of BoNT/A and /E that 
were generated by another research group. These comparisons revealed that the 
TeNT holotoxin appears to resemble the /E structure rather than /A.  
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 In total, these studies have provided novel visualizations of the two most 
potent toxins on the planet. By understanding the progenitor complex 
organization we have created a framework for understanding how the protein, 
BoNT, survives passage through the harsh conditions found in the intestinal tract 
and how the toxin design facilitates sampling and binding to the epithelial surface 
in the intestine. While the structural work on the TeNT holotoxin is still 
preliminary, I have been able to make some reasoned predictions of how its three 
domains are organized. Many structure related questions remain for both of the 
clostridial neurotoxins, some of which I have begun to address and will be 
discussed in the following section. 
 
Preliminary Data for Future Directions 
 
The HA3 – NTNH Interface 
 
 In Chapter II, I described our work on imaging BoNT PCs and detailing the 
molecular organization for serotypes /A and /B. I was unable to address, due to 
limitations in resolution, how the HA3 trimer interacted with the NTNH protein. In 
a structural sense, this protein interface is interesting because a symmetrical 
assembly of proteins (the HA3 trimer) is able to interact with an asymmetrical 
protein (NTNH). It is also interesting in a biomedical sense because this 
interaction likely contributes towards directing the toxin to the intestinal epithelial 
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cell layer. NTNH has a flexible loop at its end that is predicted to interact with the 
central pore of the HA3 trimer [225]. However, the residues involved in this 
interaction are not defined. In addition, it’s unknown if there are additional 
residues on the surface of either protein surface that contribute to this interaction.  
 A better understanding of this protein interaction will provide new research 
possibilities in the engineering of HA3-NTNH like assemblies that could target 
other cell types or provide more insight into how this interaction helps direct the 
toxin to the epithelial cell layer. This could influence the design of future drugs or 
therapeutics that are able to localize to particular areas in the body and possibly 
direct their absorption.  
 
Preliminary data  
It has been well documented in the literature that the NTNH protein 
spontaneously nicks in its flexible loop region and that once this loop is nicked 
the protein can no longer interact with HA3 [225–229]. 
We synthesized the type /A NTNH gene and had it placed into a pET24-b 
expression vector with the restriction sites NdeI and XhoI. The protein has a 
6xHis tag at the C-terminus and a predicted molecular weight of 139 kDa. 
Transformed BL-21 E. coli expressed the protein reasonably well though nicking 
of the protein was evident by Coomassie gel (Fig. 4-1). 
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Fig. 4-1. Full-length NTNH sizing column fractions. The bands from fraction 
13 were analyzed by Mass Spectrometry to confirm that the middle band was 
nicked NTNH. The lower band was from the E. coli protein ArnA. 
 
  
 Dr. Yukako Fujinaga, from Osaka University, provided us with a 
recombinant construct for type /A HA3. The HA3 gene was inserted into a 
pET52-b expression vector with the restriction sites KpnI and SalI. The protein 
has a N-terminal 6xHis tag and a C-terminal StrepTag II. An HA3 monomer has a 
predicted weight of ~70 kDa. This plasmid was transformed into BL-21 STAR E. 
coli cells for expression (Fig. 4-2). 
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Fig. 4-2. HA3 fractions from Strep-Tactin resin. S: supernatant, FT: flow 
through, W1-2: 3 mL washes with binding buffer consisting of: 1.5 M NaCl, I M 
Tris-HCl, and 10 mM EDTA, pH 8.0. E1-6: 3 mL elution fractions with binding 
buffer and 2.5 mM desthiobiotin. 
 
When the HA3 elution fractions were pooled and run over the sizing 
column, we observed that the protein tended to oligomerize into large assemblies 
but would also elute as the HA3 trimer (Fig. 4-3a). It was determined that the 
HA3 protein formed the larger assemblies as a result of concentration and that 
less concentrated protein over the column produced more trimeric HA3. Negative 
stain EM grids were prepared of the HA3 trimer (Fig. 4-3b). 
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a   b  
Fig. 4-3. HA3 purification. a) An FPLC trace of HA3 at pH 7.0. The short peak 
on the left corresponds to oligomers and the taller peak to the right corresponds 
to a HA3 trimer. b) A negative stain EM image of HA3 trimers. 
 
 
We also engineered a truncated NTNH construct that consisted of the 
toxin’s LC homolog (Fig. A-4a, the red domain). I refer to this construct as nLC 
(NTNH-LC). It is in a pET24-b expression vector with the restriction sites NheI 
and XhoI. The protein has a 6xHis tag at the C-terminus and a predicted 
molecular weight of ~50 kDa. This plasmid was transformed into BL-21 E. coli 
cells for expression (Fig. 4-4b). 
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Fig. 4-4. The nLC construct. (a) The BoNT/A NTNH molecule is shown in green 
and its LC equivalent (nLC) is colored in red [225]. (b) Sizing column fractions. 
 
 
I attempted to assess the binding of nLC and HA3 by gel filtration binding 
chromatography. Binding experiments were performed at 4° C on an analytical 
(Superdex 75) sizing column using two different buffer conditions: 50 mM Bis-
Tris, pH 5, 100 mM NaCl or 50 mM Tris, pH 7.5, 100 mM NaCl. The pH 7.5 was 
used because a previous report using a synthesized nLC-loop only construct had 
been shown to interact with HA3 up to pH 7.6 [183]. The proteins were used in 
1:1 picomolar concentrations for the binding assays. My intent with these assays 
was to establish the binding interaction between the two proteins. I planned to 
generate a series of HA3 point mutants to identify residues important for binding. 
Any binding interaction at pH 5 could not be confirmed by Coomassie gel 
(Fig. 4-5a), or at pH 7.5 (Fig. 4-5b). 
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Fig. 4-5. nLC and HA3 gel filtration binding assays at pH 5 and pH 7.5. a) 
assay at pH 5.0. b) assay at pH 7.5. The small peaks on the left of each graph 
are unbound protein. This is likely due to the presence of nicked nLC in the 
protein sample. 
 
 I did not pursue the binding assays further because at the time I was 
having a difficult time generating enough HA3 (trimeric form) protein to try the 
assay at higher concentrations. I also felt that the presence of nicked nLC was a 
variable that could not be controlled and compromised the assay. 
 I did not have a chance to try co-crystallization trials with nLC and HA3, 
but I think this is worth pursuing. 
 
BoNT/E Accessory Proteins 
 
 There is very little known about the additional genes in the BoNT/E gene 
locus: OrfX1, OrfX2, or p47. The Orf proteins are predicted to be accessory 
proteins to the neurotoxin but there is currently no evidence to support this claim. 
The purified BoNT/E PC we received from List Biologicals for our EM 
characterization did not include these proteins. With many thanks to Dr. Yukako 
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Fujinaga, we now have recombinant constructs for all three proteins. It would be 
interesting to pursue both structural and functional elements of these proteins as 
virtually nothing is known about them. 
 It would also be interesting to determine the high-resolution structure of 
the BoNT/E PC. This is comprised of two proteins: the neurotoxin and NTNH. As 
discussed earlier, the functional domains of the /A and /E neurotoxins are 
organized very differently from one another. The recent structure of BoNT/A and 
its NTNH showed that the proteins had the same structure and formed a 
protective complex by interlocking with one another. The RBD of BoNT/A 
underwent a large conformational shift when in complex with NTNH. Since The 
RBD and LC of type /E are positioned on the same side of the translocation 
domain, any conformational changes that occur from interacting with NTNH are 
hard to predict. In light of what’s known about the BoNT/A-NTNH structure, many 
questions can be raised. Does the rearrangement of the binding domain 
influence the ability of the toxin to access its receptor or does it only act to protect 
the binding domain from proteolysis?  
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High-Resolution TeNT 
 
 I have also worked to crystallize the TeNT holotoxin and am encouraged 
by my preliminary results. It would be very interesting to have a high-resolution 
structure of the molecule to compare and contrast to its BoNT homologs. I am 
especially interested to know on an atomic level how TeNT may resemble 
BoNT/E and if it does, could it be engineered to interact with the type /E NTNH 
protein? Would this be sufficient to make TeNT orally toxic? Is there a structural 
difference between BoNT and TeNT that impacts how the toxin is sorted in the 
motor neuron?  
 
Preliminary data on high-resolution TeNT 
 As mentioned earlier, the TeNT holotoxin structure is currently unknown. 
My negative stain analysis suggests that the structure is similar to BoNT/E. 
Additional EM work on TeNT should include domain assignment. This could be 
attempted with monoclonal antibody or gold nano-particles labeling. While doing 
my TeNT EM studies I also set out to crystallize the TeNT protein. The protein 
was purified as described in Chapter III Methods and was used for crystallization 
trials at a range of concentrations in un-nicked or nicked forms. The commercial 
broad screens Crystal Screen I & II, Index (from Hampton) and JCSG (from 
Qiagen) were used as well as our in-house Ben Screens (i-V) and John Screens 
(I and II).  
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 One immediate observation I made was that the un-nicked TeNT was less 
soluble and quickly precipitated or “oiled out” in many of the screen conditions. 
The nicked form of the protein was more soluble in the screens and rarely “oiled 
out”.  I got promising crystal hits in Ben Screen II. These trays were set up nicked 
TeNT at 7 mg/mL. Crystals appeared after 12 days (Fig. 4-6). 
 
 
Fig. 4-6. Nicked TeNT at 7 mg/mL hits from Ben Screen II. (a) well A5, 100 
mM Bis-Tris pH 5.0, 200 mM NaCl, 25% PEG 400 (b) well A6, 100 mM Bis-Tris 
pH 5.0, 200 mM NaCl, 30% PEG 400 (c) well E5, 100 mM Bis-Tris pH 5.0, 200 
mM Ammonium Sulfate, 25% PEG 400 (d) well F5, 100 mM Bis-Tris pH 6.0, 200 
mM Ammonium Sulfate, 25% PEG 400  
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 I tried optimizing all of the hits shown above by varying the pH, salt 
concentration, and PEG 400 percentage. I got the best results using 100 mM Bis-
Tris pH 6.0, a 25% - 30% range of PEG 400, and a 200 mM – 350 mM range of 
Ammonium Sulfate. 200 mM Ammonium Sulfate and 30% PEG 400 produced the 
best crystals. They were small single rods (Fig. 4-7) (approximately 25 um x 100 
um). Some rods were harvested and sent to the Synchrotron. While a data set 
was not collected the crystals were protein and diffracted to ~8-9Å. 
 Attempts to generate larger crystals were unsuccessful. There is also the 
possibility the crystals were not TeNT and were a contaminant. For future 
attempts I recommend increasing the protein concentration and revisiting all of 
the broad crystallization screens. For any future optimization crystal trays I 
suggest varying the hanging drop sizes and the ratio between the protein and the 
mother liquor.  
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Fig. 4-7. Nicked TeNT at 8.5 mg/mL. 100 mM Bis-Tris pH 6.0, 200 mM 
Ammonium Sulfate, 30% PEG 400. 
 
 
 
 
Additional Future Directions to Consider 
 
In addition to the structure-based future directions discussed above there 
are many functional questions that remain regarding the CNTs. For example, the 
BoNT receptor on intestinal epithelial cells has yet to be defined. It is unknown if 
gangliosides, a protein receptor, or both are required for BoNT binding to the 
epithelial cell. Our lab possesses a siRNA (small interfering RNA) library screen 
that could be used towards this receptor identification.  
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BoNT oral toxicity is largely due to its ability to form PCs that protect it 
from degradation but research has also shown [182] that ingestion of large 
quantities of pure BoNT can be toxic. This suggests to me that TeNT can also be 
orally toxic if consumed in large enough quantities. If so, it would be of interest to 
use the siRNA screen to identify it’s intestinal epithelial cell receptor. This also 
raises the question as to why C. tetanii spores in the intestinal tract do not result 
in tetanus cases in infants whereas infants are at risk of botulism if C. botulinum 
spores are ingested. Research in germ-free mice concluded that C. tetanii spores 
do not germinate in the intestine [230] but the reason for this remains unclear. 
Presumably, C. tetanii and C. botulinum spores require different environmental 
conditions for germination aside from an anaerobic habitat. The complete 
genome for C. tetanii and many C. botuilnum strains have been determined. 
Additionally, it is now known that C. botulinum has quorum sensing systems 
[231] and two-component systems (reviewed in [45]). I think it would be 
interesting see how the C. tetanii genome and C. botulinum genomes differ with 
regard to these signaling mechanisms. 
It is also of interest to define the role of BoNT-PC HA proteins in 
absorption in the gastrointestinal tract. We are in possession of recombinant 
constructs for the three HA proteins that are part of the BoNT/A and /B PC (HA1, 
HA2, and HA3). It would be interesting to incorporate a fluorescent marker into 
each of theses proteins and visualize their interaction with columnar, intestinal 
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epithelial cells using confocal microscopy. Our siRNA screen could also be useful 
for identifying key cellular components required for HA absorption. 
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